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Title: A Study of the Behavior and Localization of Pt(II) Azide and Alkyne-Modified 
Derivatives in Cells Using Bioorthogonal Chemistry and Fluorescence Microscopy 
 
Despite their ubiquitous use, Pt(II) anti-cancer drugs still suffer from many issues 
such as off-drug target effects, renal and nephrotoxicity as well as acquired and intrinsic 
drug resistance. To obtain a better understanding of how to mitigate these deleterious 
effects can be mitigated we first must know all the targets of these drugs. Highlighted in 
this dissertation is previous work performed by groups exploring the localization of Pt in 
cells using fluorescence microscopy. While Pt drugs such as cisplatin contain no native 
fluorescence, a great deal of work has been done to covalently modify complexes with 
fluorescent tags. From studies using this technique, it been reported that Pt can target a 
number of compartments within the cell ranging from the nucleus to the cytoplasm. With 
each different derivative being observed in varied cell lines it becomes difficult to 
deconvolute a universal pattern to where Pt localizes, furthermore, the connected 
fluorophore could also bias Pt localization. 
To add general functionality and eliminate the bias of a pre-tethered fluorophore 
our lab has developed a number of different azide and alkyne-modified complexes that 
append a “reactive handle” to Pt compounds. This modification allows for use of the 
bioorthogonal azide-alkyne click reaction we are able to observe Pt localization after 




to our Pt complexes in vitro and in cell cultures. We examined a number of different cell 
lines and observed frequent localization in the nucleolus of the cell. Also in this work is 
the development of methods to append multiple fluorophores to each Pt site to increase our 
ability to visualize these complexes in cells. Finally, we have also constructed a new Pt-
azide that exhibits slower exchange kinetics due to a chelating exchangeable group. The 
use of this new complex will enable studies to determine whether changing the leaving 
group results in differential localization of Pt drugs in cells. 
The work presented here has both published and unpublished co-authored material. 
Chapter II has contributions from Dr. Jonathan D. White, Rachael M. Cunningham, Andrea 
N. Loes, Prof. Michael M. Haley and Prof. Victoria J. DeRose. Chapter III contains 
contributions from Regina M. Wirth, Dr. Jonathan D. White, Aurora L. Ginsberg, Prof. 
Michael M. Haley and Prof. Victoria J. DeRose. Chapter IV contains contributions from 
Regina M. Wirth, Dr. Jonathan D. White, Alison Wallum, Prof. Michael M. Haley and Prof. 
Victoria J. DeRose. Chapter V contains contributions from Regina M. Wirth, Emily Reister-
Morris, Alison Wallum, Michael M. Haley and Prof. Victoria J. DeRose. Chapter VI contains 
contributions from Matthew M. Cerda, Rachael M. Cunningham, Michael M. Haley and 
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 Dubbed the “penicillin of cancer”,1 cisplatin is one of the most widely used anti-
cancer drugs today and is prescribed in 50-70% of treatment regimes.2 Since its FDA 
approval in 1978, cisplatin and other Pt-based anti-cancer drugs have been the vanguard of 
small molecule crosslinking agents in cancer treatment (Fig 1.1).  
 
 
Figure 1.1. FDA approved Pt-based anticancer drugs: cisplatin, carboplatin and 
oxaliplatin. 
 
 Despite their widespread adoption, Pt-based anti-cancer drugs suffer from a myriad 
of issues. A primary issue of Pt drugs is the off-target drug effects such as renal toxicity, 
peripheral neuropathy, ototoxicity, and myelotoxicity. Furthermore, patients can develop 
intrinsic and acquired cellular resistance in prolonged treatment courses.5 Ultimately, being 
able to understand the behavior and targeting of these drugs will afford us even better 
treatment regimens while minimizing undesirable side effects. This can only be done by 
being able to identify Pt targets with greater certainty and understand what factors direct 
Pt to these targets.  
 The general reactivity of these complexes stems from two exchangeable groups and 
two non-exchangeable groups coordinated to the Pt(II) center. The amine linkages on Pt 





the carboxylic acid ligands (in the cases of carboplatin and oxaliplatin) can exchange with 
water, or with biomolecules within a cell. Once Pt-biomolecule adducts are formed they 
lead to cell cycle arrest and can ultimately cause cell death if not repaired. The ability of 
serum albumins to transport Pt within cells, as well as cell influx and efflux, is not fully 
elucidated. Understanding these mechanisms could also aide in understanding targeting as 
well. 
 Because of their intrinsic simplicity, Pt-based drugs are rather hard to study via 
spectroscopic methods. Unlike carbon-containing drugs, Pt therapeutics are much more 
difficult to track through methods relying on isotopically labelled nuclei. Inherently 
insensitive 195Pt and 15N nuclei and exchangeable amine protons preclude NMR as an easily 
accessible technique for studying these drug interactions within living cells. On a bulk 
level, a number of groups have explored utilizing mass spectrometry to identify Pt targets, 
but these methods rely on fractionating cells with greater accuracy and give very little detail 
on the specific Pt targets. These complexes also lack native fluorescence, further increasing 
the difficulty to study them in vivo through imaging based techniques.  
 A number of groups have explored functionalizing Pt drugs with a fluorophore to 
track Pt localization. Furthermore, our group as well as others have explored post-treatment 
fluorophore conjugation to gain insight on Pt localization. Herein we will discuss the 
outcomes, advantages and disadvantages of pre and post-treatment fluorophore-Pt 
conjugation. 
 
Pt-fluorophore conjugation and imaging 
 One of the first reported Pt-tethered fluorophore complexes was made by Reedijk 





(U2-OS)3. Utilizing the carboxy-fluorescein moiety they witnessed broad fluorescence 
across the cell in the first hours, followed by localization primarily in the nucleus (Fig 1.3). 
After 24 h, there was sparse localization outside of the nucleus (less than 1% of the 
carboxy-fluorescence in the early hour marks) shown to be localization within the Golgi 
(by co-localization, Fig 1.4). As a control, the group also compared the distribution of the 











Figure 1.2. Cisplatin derivatives functionalized with a tethered fluorophore or an azide (for 









Figure 1.3. Brightfield and fluorescent images of U2-OS cells treated with 1. In the first 
hours a broad fluorescent intensity is seen across the cell. Panels A and D show bright 
field images of the cells, panels B and E show the fluorescent channel, and panels C and 
F show the overlays of A/B and D/E respectively.3 
 
 
 The distribution of 3 in the first hours was quite similar to that of 1, showing that 
the fluorescein unit could be directing the Pt complex. Howell and co-workers later showed 
that 1 is primarily localizing within vesicles of ovarian carcinoma 2008 cells, extensively 
mapping its trafficking into the Golgi and lysosomes as well as vesicles belonging to 
secretory pathways4. After 24 h, there was little to no intracellular signal for 3, which is in 
contrast to the apparent Golgi localization of 1 (Fig 1.5). 
 
 
Figure 1.4. Brightfield (A) and fluorescent imaging (B and C) of U2-OS cells treated with 
1 for 24 h. Co-localization analysis of 1 with a Golgi-selective stain shows a high 






 They also witnessed that 1 is less cytotoxic than cisplatin, but this difference is not 
dramatic. It should be noted that amine chelators of Pt complexes have been previously 
shown to be better tolerated by cells5. 
 
 
Figure 1.5. Treatment of U2-OS cells with 3 for 2 and 24 h. Early treatment shows broad 
localization of 3, but after 24 h the fluorescent response not present. Panels A and D show 
bright field images of the cells, panels B and E show the fluorescent channel, and panels C 
and F show the overlays of A/B and D/E respectively.3 
 
 Farrell and co-workers investigated the synthesis and localization of 4 and 5. Unlike 
previous complexes, 4 utilizes an NBD fluorophore and does not use an amine chelate6. 
Treatment of A2780 ovarian carcinoma cells with 4 and 5 in the presence and absence of 
human serum albumin (HSA) resulted in differences in localization. It was shown that 4 
localized within the nucleus and cytoplasm in the absence of HSA, but in the presence of 
HSA was limited to the lysosomal and cytosolic areas (Fig 1.6A). Complex 5 showed 
nuclear/nucleolar localization in the presence and absence of HSA (Fig 1.6B). More 
importantly, these studies had shown that the presence of albumins can affect uptake and 








Figure 1.6. A2780 cells labelled with 4 and 5. The top two panels are cells labelled with 
4, incubated in the presence and absence of human serum albumin (HSA). A significant 
amount of fluorescence is lost when 4 is incubated with HSA. The bottom two panels are 
cells labelled with 5, in the presence and absence of HSA. HSA does not seem to affect the 
localization of 5.5 
 
 
 Hall and co-workers constructed two BODIPY modified Pt complexes (6 and 7) 
and compared both their localization and ability to induce DNA damage against 1, 
cisplatin, and ethylene diamine-Pt (Fig 1.7) in KB3-1 cells, human cervical carcinoma 
cells7. To assess DNA damage, the group monitored phosphorylation of H2A.X by 





concentrations (100 µM), 1 and 2 did not appear to induce DNA damage. Complexes 6 and 
7 appeared to induce some DNA damage at 50 µM, and this response was also seen in the 
cisplatin control of 5 µM. The two BODIPY-Pt complexes showed localization within the 
nucleus and cytoplasm, with punctate staining within the nucleus which could be nucleolar 
localization. 
 Furthermore, when the group explored the uptake of 6 and 7 in resistant cell lines 
(KB-CP.5 and KB-CP20) they noticed a reduction in accumulation (monitored by flow 
cytometry) in comparison to cisplatin. This could indicate that cellular uptake of Pt-
fluorophore complexes might be different to that of cisplatin. Ultimately, this difference 
could be what is influencing Pt-fluorophore complexes cytotoxicity and targeting. 
 
 
Figure 1.7. KB-3-1 cells treated with Pt-fluorophore conjugates. Panel A is a control set 
of images with no treatment. Panels B-D are treated with the non-fluorescent Pt species: 
cisplatin (B), ethylene diamine-Pt (C), 8 (D). Panels E-H are cells treated with 1, 2, 6, and 
7 respectively. Panels are falsely colored blue for DAPI staining, magenta for H2A.x 






Mono-Functional Fluorophore-Tethered Cisplatin-Like Complexes 
 While cisplatin is a bi-functional crosslinking complex, some groups have also used 
monofunctional crosslinking complexes to study Pt localization.8-10 Zhang and co-workers 
have shown with 9, a thioflavin modified Pt complex, that targeting of nuclear as well as 
mitochondrial and lysomal bodies is present (Fig 8).8 Nair and co-workers were able to 
construct a turn-on fluorophore appended Pt complex, 10, that upon DNA-binding elicited 
a 21-fold increase in emission.9 Interestingly, in cells 10 does not show any fluorescence 
at or below its respective IC50 value(10 µM). Fluorescence is only present above the IC50  
 
 
Figure 1.8. Confocal fluorescence images of HeLa cells co-stained with 50 nM 
MitoTracker Red CMXRos (or 1 μM LysoTracker Red DND-99) and 20 μM 9 for 1.5 h. 
Panels a/d show the green fluorescence of 9. Panels b and e show the red fluorescence of 
Mito Tracker Red and Lyso Tracker Red respectively. Panels c and f show the overlays of 
their respective rows.7 
 
value, which indicated that in order to elicit a fluorescent response the cell’s viability had 
to become greatly decreased. Control studies with serum albumins did not elicit the same 
increase in emission, indicating the fluorescent turn-on is only present when 10 interacts 








Figure 1.9. Images of HeCat cells treated with 10 at 10 µM (A), 20 µM (B) and 40 µM 
(C).9 
 
 Complex 11 was used to show Pt localization within MCF-7 and A549 cell lines, 
as well as zebrafish larva10. In the human cell lines, distinct nucleolar localization is 
witnessed as well as cytoplasmic localization, most likely due to localization within the 









Figure 1.10. Confocal fluorescence imaging of MCF-7 cells incubated with 11 (10 μM): 
(a) bright-field image; fluorescence image after 0.5 h (b), 3 h (c), and 4 h (d). Also shown 
are bright-field and fluorescent images of a cross-section of zebrafish larva treated with 11 
(e).10 
 
Post-treatment fluorophore conjugation 
 
 Another approach to ascertaining localization of Pt complexes is the use of post-
treatment functionalization. This can be done by installing a group that has tailored 
reactivity, and will only react with another group appended to a fluorophore. This approach 
has been pursued by our group as well other groups to ascertain Pt targeting. In short, this 
method of analysis allows treatment of cells with a Pt complex with a minimally invasive 
reactive handle (Fig 1.11A). After treatment, the cells are fixed and the localized Pt is 
conjugated to a fluorophore. The use of this strategy allows for analysis of Pt localization 
without having the influence of additional steric bulk and/or electrostatic charges from the 
pended fluorophore. This post-treatment conjugation relies upon the azide-alkyne 





azide will selectively react and form a covalent linkage (Fig 1.11B). Both the azide and 
alkyne should only react toward each other, reducing other possible side reactions in cells. 
The relative size and lack of charge in the two species should also help reduce any bias a 





Figure 1.11. Panel A shows the generic scheme for post-treatment fluorophore 




 Bierbach and co-workers developed a system that combines a DNA intercalator (an 
acridine unit) and Pt to form a synergetic complex with a raised toxicity (12)12. This 
complex has also been modified to contain an azide group, giving the ability to analyze 
localization without having an effect of the presence of the fluorophore. The appended 
azide group will have selective reactivity, and for their purposes only will react in the 
presence of an alkyne and a copper catalyst. The group treated NCI-H460 cells, lung cancer 





conjugation. This method of post-treatment conjugation resulted in a fluorescent response 
in the nucleus and cytoplasm. Most notably the group witnessed punctate staining inside 
the nucleus ultimately owed to nucleolar localization. Unfortunately, because this method 
relies on a copper catalyst live cell imaging is not currently possible. However, the use of 
cell permeable turn-on strained alkyne fluorophores could ultimately lead to this being 
possible in future studies. At the moment, this method of analysis relies “snapshots” of Pt 




Figure 1.12. Image of NCI-H460 cells treated with 12, then fixed and post labelled with 
Alexa Fluor 488 alkyne. Cells were also stained with Hoechst for DNA labelling and Mito 
Tracker for mitochondrial labelling.12 
 
 As a means to show that the localization of 12 is not influenced by the azide 
appendage, Bierbach and co-workers also constructed 12 by labelling 13 with a strained 
alkyne fluorophore before treatment13. By incubating 12 and 13 together, they were able to 
show that the two species co-localize strongly within cells (Fig 13). They do note that 13 
has a decreased ability to target compacted chromatin, most likely due to the steric bulk of 
the dibenzocyclooctyne (DIBO) group. Furthermore, using this pre-tethered fluorophore 
Pt complex the group was able to conduct a double labelling experiment within cells using 
ethynyl modified DNA and RNA constructs (using 5-Ethynyluridine and 5-Ethynyl-2′-





treatment with a decreased production of RNA in the nucleus. Ultimately these findings 
indicate that 12 and 13 lead to a reduction of transcription.  
 
Figure 1.13. Co-localization studies of 12 and 13. Panel A shows the general scheme of 
the double labelling technique. In the presence of Cu, 12 can be conjugated to an alkyne-
modified Alexa Fluor 647 fluorophore. Panel B shows images of cells incubated only with 
12 and 13 in the absence and presence of Cu. Only in the presence of Cu is the group able 
to see fluorescence in the 647 nm channel. The merged overlay of all channels shows a 
strong co-localization of the two signals. Both the pre and post-treatment result in a strong 
nucleolar localization, followed by nuclear and cytoplasmic staining.13 
 
It should be noted, the acridine unit can also be heavily influencing localization of the 
complex as a whole. The synthetic rationale of installing the Pt complex was to increase 
cytotoxicity by giving the complex as a whole the ability to not only intercalate but to form 
a covalent linkage as well. The group does note that the azide-free version of 12 shows 





influx as well. Further work needs to be done to ascertain the effect of such reactive 
handles. 
 The two approaches listed here can be used to ascertain how these Pt complexes 
behave in vivo. Utilizing a pre-tethered Pt-fluorophore complex we can gain insight on how 
the localization of Pt changes as a function of time. Use of the turn-on complex 1 can also 
help mitigate background fluorescence. Ultimately, the question of if the appended 
fluorophore affects localization is still present. Results in cisplatin resistant cell lines, 
lowered toxicities, and inconsistent action of DNA damage begs the question of if they 
behave in the same manner as cisplatin. The use of post-treatment functionalization is also 
an encouraging route, but the methods currently explore ascertain more the localization of 
a pro-drug prefaced on intercalation followed by covalent modification of DNA. Our work 
focuses on the use of post-treatment fluorophore conjugation of systems more similar to 
the small molecule crosslinking one of cisplatin. Herein, the focus for this body of work 
will be in the method development and characterization for cellular imaging of azide and 
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CONVENIENT DETECTION OF METAL-DNA, METAL-RNA, AND 
METALPROTEIN ADDUCTS WITH A CLICK-MODIFIED PLATINUM (II) 
COMPLEX 
  
 This chapter has contributions from Dr. Jonathan D. White, Rachael M. 
Cunningham, Andrea N. Loes, Prof. Michael M. Haley and Prof. Victoria J. DeRose. MMH 
and VJD provided insight and direction through the course of this investigation. JDW 
performed the synthesis and prepared samples for Pt-bound DNA samples for dPAGE 
analysis. RMC performed studies using Pt-bound bovine serum albumin (BSA) and 
analyzed them via SDS-PAGE, while ANL performed experiments treating S. cerviscea 
and subsequent RNA extractions. All HPLC analysis and mass spectrometry sample 
preparation were done by myself. This chapter includes material reproduced from Dalton 
Transactions (2015, 44, 3536-3539, © 2015 Royal Society of Chemistry), co-authored by 
JDW, myself, RMC, ANL, MMH, and VJD. JDW and I co-wrote this manuscript with 
extensive input from VJD. 
 
High-Yielding Pt(II) Reagents for Post-Binding Covalent Modifications 
 Platinum(II)-based drugs are administered in many anticancer treatment 
regimes;1 however, a broad identification of Pt-specific cellular targets is still lacking.2 As 
Pt(II) compounds are effective nucleic acid crosslinking agents, they also have potential as 
structure probes in complex RNAs.3 Click-functionalized Pt reagents provide a reactive 





identification of Pt-bound species. We recently described a new pyridine-based Pt click 
reagent, picazoplatin (1, Fig. 2.1).4 Despite the wide use of click chemistry and importance 
of platinum therapeutics, only one other recently reported compound, an extended Pt-
acridine therapeutic, is available for post-treatment click analysis.5 In the case of 
picazoplatin, relatively slow reaction kinetics are built into the design of the parent 
compound picoplatin wherein the ring methyl shields Pt from substitution 
reactions.6 Moreover, although in-cell use was demonstrated, analysis of cellular targets 
may be complicated by the potential for trans-labilization of the azide-functionalized 
picoline ring. New click-functionalized Pt(II) reagents are of great interest in order to take 
advantage of bioorthogonal approaches7 for high-throughput identification of Pt-bound 
species in vivo.  
 
Figure 2.1. Click-functionalized picazoplatin 1 and its parent picoplatin 2, with 
cisplatin 3 and the 1,3-propanediamine derivatives 4 and 5. 
 
 To provide a convenient and fast-reacting Pt(II)-azide click reagent, we have 
explored cis-[Pt(2-azido-1,3-propanediamine)Cl2] (4) in nucleic acid binding, protein 
binding, and click chemistry. While 4 has been previously used to create libraries of 
diazenecarboxamide–carboplatin conjugates,8 to our knowledge it has not been applied as 
an agent for post-treatment labelling by click modification. Herein, we demonstrate 





differentiation of 4 when bound to duplex DNA. Click fluorescent labelling of Pt-bound 
proteins is demonstrated in bovine serum albumin (BSA). The utility of this compound 
for in vivo studies is demonstrated by tracking Pt-bound ribosomes from cells treated 
with 4. 
 DNA binding studies of 4 on a 13-nucleotide DNA containing a single GG site 
were analysed by dPAGE (Fig. 2.2). A higher yield of 4-bound DNA is observed in 
comparison with the sterically-hindered 1. Subsequent click reactivity with a dansyl alkyne 
fluorophore is seen in both cases. 
 
Figure 2.2 (A) Reaction scheme for Pt binding and subsequent click to an alkyne 
fluorophore. (B) dPAGE analysis of dsDNA bound by picazoplatin (1) and cis-[Pt(2-azido-
1,3-propanediamine)Cl2] (4) and subsequently clicked to a dansyl alkyne fluorophore. The 
denatured DNA strands are visible in lane 1, while higher molecular weight Pt-bound 
species are visible in lanes 2 and 3. Click reaction results in fluorescence of the Pt–DNA 








RP-HPLC Analysis of DNA-Bound Pt Adducts 
 To further quantify Pt binding and click reactivity of 4, HPLC analysis was used 
with a short DNA hairpin sequence (TATGGTATTTTTATACCATA, HP). Upon Pt 
binding to the single GG site, two product peaks emerge that are distinct from the parent 
DNA peak. Both new peaks were confirmed by dPAGE to contain hairpin DNA bound by 
Pt (see Appendix A). Both products contain one bound Pt(2-azido-1,3-propanediamine) as 
confirmed by identical 3+ charged ions in ESI-MS analysis (Fig. 2.3C). When reacted with 
dansyl alkyne, material in both product peaks yields clicked products as resolved by HPLC 
and identified by the fluorophore absorbance at 340 nm (>80% yield, see Appendix A). 
Thus, this bimodal product distribution is hypothesized to originate from two different 
structural isomers of 4 bound to the asymmetric DNA strand. This hypothesis was tested 
with the analogous azide-free complex 5 (see Appendix A).9 As expected, the HPLC trace 
of DNA-bound 5 exhibits only one product peak (Fig. 2.3B), indicating that the 2-azido 






Figure 2.3 HPLC absorbance traces at 260 nm for a short hairpin DNA sequence bound to 
(A) 4 and (B) 5. Peaks observed at ∼37 mL eluent volume are identified as unbound DNA, 
and peaks between ∼40 and ∼42 mL are Pt-bound DNA (55–65% yield). When 4 is bound 
to DNA, two peaks are resolved indicating the presence of non-equivalent Pt-bound 
species. Both collected fractions (blue and red traces) were analysed via ESI-MS, revealing 
that they contain the same 3+ charged species of 4-bound DNA (C). Reaction with azide-
free 5 yields a single product band (B, 55–65% yield). Normalized areas are indicated 
above peaks of interest. 
 
 The two isomer products of 4-treated hairpin DNA consistently yield non-
equivalent peak areas, indicating preference of one conformation that is likely being 
dictated by the orientation of the azide relative to the helix. Supporting this, treatment of 





the same sequence in duplex returns to an unequal population (Fig. 2.4D, see also 
Appendix A). 
Possible conformations of DNA-bound 4 are visualized (Fig. 2.4) in molecular models 
built by substituting 4 into the crystal structure of cisplatin-bound 12-mer DNA duplex 
(pdb: 3LPV).10 Bond lengths and angles around the Pt(II) center were fixed and the 
position of the DNA was locked (see Appendix A), and equilibrium geometries of the two 
structural isomers were determined using molecular mechanics (MMFF). The resulting 
models show distinct geometric properties, with the azide oriented either toward the major 
groove or towards the phosphate backbone. In the denatured strands analyzed by HPLC, 
these isomers must give rise to slight differences in hydrophobicity; resolution of such 
minor differences in oligonucleotides has precedent.11,12 The inequivalent populations of 
isomers suggest that the helical structure of DNA has a direct impact on the preferred 
orientation of the azide substituent due to steric and electronic effects. Like the hairpin 
DNA, upon reaction with the dansyl alkyne fluorophore, 4-bound T6GGT5 is converted 









Figure 2.4 Molecular modelling (MMFF) of the two possible isomers of 4-bound double-
stranded DNA with the azide oriented in towards (A) or out from (B) the centre of the 
helix. In the helical conformation of A as shown, the azide moiety is less solvent exposed 
than in B. Models were generated by substituting 4 into the crystal structure of cisplatin-
bound DNA (PDB: 3LPV, see Appendix A). The adjacent Pt-bound guanines of the 
intrastrand crosslink are shaded purple. HPLC absorbance traces at 260 nm for 4 reacted 
with (T6GGT5) as a single-strand (C, 55–65% yield) or in duplex (D, 55–65% yield). 
Normalized areas are indicated above peaks of interest. When reacted with the single-
strand sequence, isomers of 4-bound DNA show equal population (ratio = 0.96 ± 0.05; see 
Appendix A for data in triplicate) whereas they are unequal for the duplex (ratio = 1.3 ± 







Metal-Protein and Metal-RNA Pt-Binding Analysis 
 In furthering the analysis of potential targets for Pt(II) compounds, bovine serum 
albumin (BSA) was also investigated as a model compound for the ability of 4 to bind and 
participate in post-treatment labelling of proteins. Previous studies have shown Pt-binding 
to Cys 3413 following treatment of BSA with cisplatin. Here BSA is incubated with 
increasing equivalents of 4 followed by click to an alkyne-containing dansyl fluorophore 
(Fig. 5). Labelled protein was visualized by Coomassie staining and fluorescence imaging. 
Fluorescence is seen only in the 4-treated samples and increases in a dose-dependent 
manner (Fig. 2.5, lanes 2–4). Fluorescence is also only observed in reactions containing 
both 4 and the Cu catalyst. 
 
Figure 2.5 Fluorescent labelling by click chemistry of 4-treated bovine serum albumin 
(BSA) with a dansyl alkyne fluorophore. Lanes 2–4 contain BSA incubated in the presence 
of CuSO4 post Pt treatment and show a dose-dependent increase in fluorescent signal with 
respect to the concentration of 4. Lanes 1 and 5 shows that fluorescent labelling is also 
dependent on the presence of both 4 and the Cu catalyst. 
 
Ultimately, the power of clickable Pt compounds is to identify and analyze in vivo targets. 





ethylenediamine and 1,3-propanediamine are better tolerated by cells, making them 
particularly attractive as potential in vivo crosslinking reagents.14 We have previously 
shown significant accumulation of Pt on cellular RNA following treatment with cisplatin, 
with major accumulation being on ribosomal RNA.15,16 Here, we tracked the lifetime of 
Pt–RNA adducts using 4, and find surprising longevity of Pt adducts on ribosomal 
RNA. S. cerevisiae was treated with 0 μM and 250 μM 4 for 6 h and then re-suspended in 
fresh media. Cells resuspended in drug-free media showed growth similar to untreated 
control cells, consistent with the relatively low toxicity of 4 and in contrast to treatment 
with cisplatin.15 To determine whether Pt–rRNA adducts were quickly degraded or long-
lived, RNA was extracted from cells at various timepoints and accumulated Pt detected 
following click labelling with Alexa Fluor 488 DIBO (Fig. 2.6). Lanes 1–4 contain rRNA 
isolated from untreated cells subjected to the same click labelling protocol. The absence of 
fluorescence in these lanes indicates the absence of nonspecific labelling during the 
DIBO/click procedure. Lanes 5–8 contain rRNA isolated from treated cells after up to 2 h 
in 4-free media. The normalized fluorescence per rRNA band shows no significant loss in 
Pt–RNA adducts, meaning that platinated ribosomes persist in doubling cells and that the 
majority of them are not targeted for fast degradation. The persistence of the fluorescent 
labelling even after 120 min post-treatment demonstrates the efficacy of 4 in post-labelling 









Figure 2.6 Fluorescent labelling by click chemistry of rRNA extracted from 4-treated S. 
cerevisiae. 25S and 18S rRNA extracted from S. cerevisiae treated with 0 μM or 250 
μM 4 for 6 h and resuspended in drug-free media for 0–120 min. All samples were 
subsequently treated with 250 μM Alexa Fluor 488 DIBO (16 h, 37 °C). 
 
Conclusions 
 This work demonstrates the ability of azide-modified Pt(II) compound 4 to readily 
bind oligonucleotides and proteins and subsequently undergo click reactions for post-
treatment fluorescent labelling. This demonstrated reactivity of 4 expands the array of 
available azide-modified Pt(II) reagents to be used in post-treatment target analysis. In 
comparison with recently reported 1, 4 exhibits greatly increased efficiency in target 
binding. HPLC analysis and molecular modelling suggest formation of two different 
isomers of 4-bound DNA adducts, hypothesized to be biased by the orientation of the azide 
moiety of 4 in relation to the helical structure of DNA. Efforts to discern differences in 
click reactivity between the two isomers are currently underway in our laboratory, as well 
as efforts utilizing clickable Pt(II) reagents as RNA crosslinking agents to quantify and 








Summary of Chapter II and Bridge to Chapter III 
 In this chapter we analyzed the binding of 4 to DNA, RNA and proteins. Complex 
4 exhibited a bias in conformational isomers upon binding to DNA. This isomerization was 
shown to be most likely due to the presence of the azide group on 4. Furthermore, the 
isomerization bias seems to be influenced by the higher order structure of DNA. Complex 
4 also shows a propensity to form metal-protein and metal-RNA adducts as well. The RNA 
adducts on rRNA formed in vivo appear to be long-lived. Using 4 as a synthon to construct 
other Pt(II) azide-modified complexes could help give insight on Pt localization within 
cells. Chapter III uses two different derivatives of 4, an azide and an alkyne-modified 






AZIDE VS ALKYNE FUNCTIONALIZATION IN PT(II) COMPLEXES FOR 
POST-TREATMENT CLICK MODIFICATION: SOLID-STATE STRUCTURE, 
FLUORESCENT LABELING, AND CELLULAR FATE 
 
 This chapter contains contributions from Regina M. Wirth, Dr. Jonathan D. White, 
Aurora L. Ginsberg, Prof. Michael M. Haley and Prof. Victoria J. DeRose. MMH and VJD 
provided insight and direction through the course of this investigation. Under the 
advisement of JDW, RMW conducted all synthesis and dPAGE analysis of the Pt 
compounds. The synthesis of two rhodamine fluorophores and development of the in-cell 
imaging technique were done by myself. ALG, under my advisement, performed studies 
using the alkyne-appended Pt complex in HeLa cells while I investigate the azide appended 
complex within cells. This chapter includes material reproduced from the Journal of the 
American Chemical Society (2015, 44, 3536-3539, © 2016 American Chemical Society), 
co-authored by RMW, JDW, myself, ANG, MMH, and VJD. 
 
Introduction 
 Since the compound cisplatin, cis-diamminedichloroplatinum(II), was approved by 
the FDA for clinical use in 1978, Pt-based therapeutics have become one of the most widely 
used and successful treatment options for a variety of cancers, including ovarian, testicular, 
bladder, non-small-cell lung carcinomas, and others.1-4  Although much progress has been 
made in understanding the mechanisms of action of Pt compounds as well as their specific 





lacking.5-8 It is generally accepted that Pt reagents are taken up into the cell via passive and 
active mechanisms and then undergo aquation, the displacement of labile chloride ligands 
by water, forming [Pt(NH3)2Cl(OH2)]
+ and [Pt(NH3)3(OH2)2]
2+ species.9,10 These highly 
reactive species form exchange-inert complexes with purine bases of genomic DNA in 
addition to other biomolecules.11 In vivo and in vitro studies have unambiguously 
identified cis-1,2-{Pt(NH3)2}
2+-d(GpG), 1,2-d(ApG), and 1,3-d(GpNpG) intra- and 
interstrand DNA cross-links as products, and these are capable of inhibiting normal 
transcriptional processes of the cell and initiating apoptotic signaling.12,13 Importantly, only 
a very small fraction of Pt (less than 10% in the case of cisplatin) accumulates within 
genomic DNA.14 In samples isolated from cells treated with Pt reagents, Pt has been found 
to bind to a wide variety of additional nucleophilic targets, including different cellular 
RNAs, proteins, and sulfur-containing compounds such as glutathione. Despite a great deal 
of work, Pt localization in treated cells and binding properties with non-DNA targets, and 
their consequences, remain poorly understood.6,7,15 A better understanding of Pt cellular 
reactivity is essential in order to design new, more effective therapeutics and methods of 
delivery. 
 In addition to identifying molecular targets of Pt reagents, a comprehensive 
identification of all organelle targets is desired. Such an understanding would shed light on 
apoptotic and toxicity pathways, as well as differences in efficacy in dissimilar types of 
cancers. Highlighting the diversity of potential cellular locales, various studies using atom-
based techniques as well as fluorescent tagging have obtained evidence for cellular Pt 
accumulation in ribosomes, the nucleus, nucleoli, mitochondria, and secretory pathways 





Fluorescence detection via confocal microscopy has distinct advantages of sensitivity and 
resolution and can be coupled with existing fluorescent markers for co-localization studies. 
An important strategy used to detect Pt in cells comprises the covalent tethering of 
fluorescent probes to modified Pt-coordinated ligands. In one such study, a fluorescein-
linked Pt compound was observed to accumulate in the nucleus and nucleolus 2–3 h post-
treatment, followed by punctate localization in the cytoplasm after 7 h. A gradual decrease 
in total cellular fluorescence was observed over several days, indicating that Pt actively 
effluxes from the cells.17 Other Pt–fluorescein conjugates have revealed accumulation in 
the Golgi and in vesicles, and expression of Cu efflux proteins was demonstrated to affect 
Pt retention.18 Other important conclusions regarding the reactivity of Pt compounds have 
been determined via modification with fluorescent probes, and these have been reviewed 
recently.19 While fluorophore-linked Pt probes have been shown to mimic some properties 
of native Pt complexes, the physical properties of the large, hydrophobic probes and their 
interactions within the cell are expected to be quite different from those of the small, neutral 
or positively charged Pt complexes.8,17-20 These differences may influence the types of 
interactions that direct localization of the Pt complex, such as intercalation, hydrophobic, 
or electrostatic-based interactions. It has been shown, for example, that different amino-
acid-linked cisplatin analogues exhibit altered specificity for ribosomal RNA (rRNA) 
compared to the parent compound.21  
 Due to possible undesirable consequences of pre-attaching probes, fluorescence 
detection of Pt compounds through post-binding modifications would be more attractive. 
This strategy takes advantage of minimally invasive reactive handles incorporated onto Pt 





irreversibly to biomolecule targets (Fig 3.1). Using this strategy, we have previously 
reported use of the Cu-catalyzed azide–alkyne cycloaddition (CuAAC) click 
reaction,22 with modified Pt(II) complexes containing azide- and alkyne-reactive 
“handles”.23-26 We have identified cellular RNAs, including tRNA, as targets of Pt 
reagents in vivo, in addition to identifying other nucleotide and protein targets in vitro.23-
27 Recently, Bierbach and colleagues have used post-binding click modification of a 
monofunctional Pt–acridine hybrid complex to identify its cellular distribution within the 
nucleus and nucleoli of lung cancer cells.20a,20b Herein, we report the design and use of the 
new click-capable Pt(II)–azide complex 1 and its cellular distribution in HeLa cells, as 
observed via confocal fluorescence microscopy. The in-cell and in vitro reactivity of 1 is 
also compared with that of the previously reported alkyne-modified 
congener 2,26 demonstrating the utility of the completely complementary pair of Pt–click 
reagents and rhodamine–fluorophore probes. Both compounds 1 and 2 were designed to 








Figure 3.1. (a) Chemical structures of the anticancer drug cisplatin, with the novel azide-
appended 1 and alkyne-appended 2. (b) Reaction scheme of target-bound 1 undergoing 
post-binding covalent click modification to a fluorescent probe. 
 
Results and Discussion 
 Compound 1 was synthesized analogously to the preparation of 2, with the peptide 
linkage allowing for facile incorporation of different coupling partners (Fig 
3.http://pubs.acs.org/doi/10.1021/jacs.5b09108 - fig22). Therefore, di-tert-butyl (2-
aminopropane-1,3-diyl)dicarbamate was coupled to 4-azidobutanoic acid with 1-ethyl-3-
(3-N,N-dimethylaminopropyl)carbodiimide.28 Deprotection with anhydrous HCl followed 
by platination of [Pt(DMSO)2Cl2] yielded the final product 1 in 16% overall yield. Both 
complexes 1and 2 exhibit identical 195Pt NMR chemical shifts (δ = −2286 ppm, d7-DMF; 
see Appendix B), indicating no inter- or intramolecular interactions between the Pt center 






Figure 3.2. Synthesis of Pt complex 1. Boc = tert-butoxycarbonyl, EDC = 1-ethyl-3-(3-
N,N-dimethylaminopropyl)carbodiimide, DMSO = dimethyl sulfoxide, DBU = 1,8-
diazabicyclo[5.4.0]undec-7-ene, DMF = N,N-dimethylformamide. 
 
Crystals of 1 suitable for X-ray diffraction were obtained from a chilled DMF/H2O 
solution, and the structure obtained confirms that assigned via NMR spectroscopy. The 
individual bond lengths and angles around the square planar Pt(II) center of the azide-
containing 1 are very similar to those of the reported alkyne-appended 2 (see Appendix 
B).26,30 Both compounds form Pt–Pt dimers (Pt···Pt, 3.46 Å in 1) connected in the crystal 
structure by hydrogen bonds (Fig 3 and Appendix B).31, 32 Each chloride acts as a 
hydrogen bond acceptor for the Pt-coordinated amine groups (Cl···N, 2.53 Å, 2.35 Å in 1) 
(Fig 3.3a).32 In addition, a distance of 2.13 Å between coordinated amine protons and 
adjacent carbonyl oxygen indicates hydrogen bonding (see Appendix 
Bhttp://pubs.acs.org/doi/suppl/10.1021/jacs.5b09108/suppl_file/ja5b09108_si_001.pdf, 
Figure S3). 
 Despite the similarities in the solid state between 1 and 2, the broader packing 
arrangement changes drastically upon exchange of the alkyne with the azide moiety. The 
arrangement of 2 is primarily dictated by CH/π(C≡C) hydrogen bonds, forming a rare, 





be dictated by the formation of the Pt dimer, including both Pt–Pt bonding and hydrogen 
bonds. The Pt centers are aligned into infinite 1D-zigzag chains with regular alternating 
distances of 3.46 and 3.98 Å and a Pt···Pt···Pt bond angle of 159.6°. Interestingly, the 
azide moieties of adjacent Pt “chains” are aligned antiparallel and in close proximity to one 
another, approximately 3.5 Å apart (Figure 3.3b). This is in agreement with azide−azide 
packing distances previously reported for several organo-azides and may indicate the 
presence of a weak dipole–dipole interaction between nitrogen atoms of opposing 
azides.33 Finally, N–N bond lengths and angles of the azide moieties themselves are in 
good agreement with well-established parameters (1.12 and 1.28 Å for the terminal and 
internal N–N bond distances, respectively, and N≡N–N bond angle of 174.1°).33, 34 
 
Figure 3.3. (a) Crystal structure arrangement of 1 showing the Pt–Pt dimer formation in a 
1D-zigzag chain with a 159.6° angle between the platinum centers as well as Cl···H–N 
hydrogen bonding. Selected bond lengths and angles: Pt–Cl 2.315(2) Å, 2.334(3) Å; Pt–N 
2.016(8) Å, 2.045(7) Å; N≡N 1.117(11) Å; N–N 1.280(12) Å; N≡N–N 174.2(11)°. (b) 
Antiparallel arrangement of the azide moieties of adjacent Pt chains. (c) Crystal structure 
arrangement of 2 showing the spoke-type arrangement dictated by CH/π(C≡C) hydrogen 






 To confirm the ability of 1 to bind known targets of Pt and subsequently undergo 
post-binding click modifications, 1 was bound to a short oligonucleotide sequence 
containing a 5′-GG-3′ pair and subsequently reacted with an alkyne-functionalized 
rhodamine fluorophore (3) (see Appendix B) and subjected to denaturing polyacrylamide 
gel electrophoresis (dPAGE). Both compounds 1 and 2 undergo facile binding to DNA (18 
h, 37 °C), followed by near-complete conversion to the rhodamine-labeled click product 
(CuSO4–ascorbate, 18 h, rt), the latter complex 2 having been reacted with the analogous 
azide-functionalized rhodamine fluorophore (4) (Fig 3.4).35 Both complexes appear to bind 
to DNA in similar yields, which suggests the identity of the click “handle” (i.e., azide 








Figure 3.4. (a) Reaction scheme of the binding of 1 and 2 to a DNA hairpin followed by 
fluorescent click-labeling using complementary alkyne- or azide-rhodamines (3,4). (b) 
dPAGE experiment showing the binding of 1 and 2 to a 5′-GG-3′ DNA hairpin (lanes 2 
and 3). The click reaction of 1- and 2-bound hairpin with the complementary rhodamine 
fluorophores can be observed by the appearance of a fluorescent band (lanes 4 and 6). 
Control reactions show no click ligation under Cu-free conditions (lanes 5 and 7). 
 
 Further in vitro experiments were conducted to obtain deeper insight into the 
binding and click reactivity of 1. Since we now possessed two complementary click-
appended Pt(II) complexes, we were curious if they could be reacted together to covalently 





GG-3′ DNA hairpins, then reacted together under click conditions analogous to the 
previously described reactions with rhodamine (24 h, rt). The appearance of a band of 
significantly less mobility indicates the formation of the triazole-linked hairpin DNA dimer 
(lane 4, Figure 3.5). This result suggests the potential for these Pt compounds to be used in 
nucleotide cross-linking applications and other diverse nucleotide modification reactions.36 
 
 
Figure 3.5. (a) Reaction scheme of biomolecule-bound azide 1 clicking to the 
biomolecule-bound alkyne 2 to form a cross-linked DNA. (b) dPAGE experiment 
showing 1 and 2 bound to a 5′-GG-3′ DNA hairpin (lanes 2 and 3). Lane 4 shows the click 
reaction product between 1- and 2-bound DNA hairpins, resulting in a triazole-linked DNA 






To assess the influence of the peptide linkage of 1 (and 2) on DNA binding and click 
reactivity, we compared 1 to the peptide- and linker-free cis-[Pt(2-azido-1,3-
propanediamine)Cl2] (5).
37 Compound 5 has been previously utilized by our group for 
post-treatment fluorescent click labeling of nucleotides and proteins in vitro, and rRNA in 
vivo.25 
 For comparison, 1 and 5 were each bound to a 5′-GG-3′ DNA hairpin sequence and 
subjected to click conditions with a dansyl alkyne fluorophore (Fig 3.6a) and analyzed via 
dPAGE (Fig 3.6b). Both compounds appear to bind to DNA in similar yields (lanes 2 and 
3), indicating binding reactivity independent of the linker moiety. The click reactivity was 
evaluated by time-dependent (0.5, 3, or 6 h reaction times) treatment of the Pt–DNA 
complex with the dansyl–alkyne fluorophore under click conditions. Interestingly, 1-bound 
DNA is completely converted to clicked product after only 3 h reaction time, whereas even 
after 6 h click reaction time, unreacted (non-clicked) 5-bound DNA is observed (Fig 3.6, 
lane 8). The observed enhanced reactivity of the longer 1 may be due to increased steric 
accessibility of the azide moiety once bound to DNA. Additionally, non-innocence of the 
peptide bond participating in the click reaction cannot be ruled out—for example, Ting and 
colleagues reported an acceleration of the CuAAC reaction using organo-azides that 






Figure 3.6. (a) Reaction scheme of binding of the azide-modified Pt(II) 
complexes 1 and 5 to a 5′-GG-3′ DNA hairpin sequence, followed by subsequent CuAAC 
with dansyl alkyne fluorophore. (b) dPAGE analysis of binding and fluorophore 
conjugation of 1 and 5 to DNA hairpin (see Appendix B for conditions). 
 
 Encouraged by its apparent enhanced reactivity, we pursued cellular localization 
studies using the azide-appended 1 and confocal fluorescence microscopy (Fig 3.7). In 
initial studies, HeLa cells were treated with 1 (25 μM, 3 h), washed, fixed and 
permeabilized, and then labeled with the alkyne-containing rhodamine fluorophore 3 (5 
μM, 2 h) under CuAAC click conditions (see Appendix B). Confocal images of the cells 
show the highest level of fluorescence in the nucleoli of the HeLa cells, along with broad 
localization in the nucleus (Fig 3.7b). Importantly, the Cu-free controls show no 
fluorescence from nonspecific fluorophore interactions (Fig 3.7f and Appendix B). These 





accumulation of compound 1 in the nucleoli is in agreement with previously identified 
nuclear DNA adducts of Pt,10 as well as Pt–rRNA adducts. rRNA has been shown to bind 
Pt(II) complexes using inductively coupled plasma mass spectrometry and fluorescent 
labeling in Saccharomyces cerevisiae.24, 27 Pt–protein adducts may also be present. The 
nucleolus has also been identified as a major target using some fluorophore pre-tethered 
Pt(II) complexes.39 Bierbach and colleagues very recently identified localization in the 
nucleolus using an azide-modified Pt–acridine complex for post-binding fluorescent 
labeling as well as pre-tethered Pt–fluorophores, although differences between the two 
approaches were noted.20a, 20b 
 Treatment of HeLa cells using the complementary alkyne-containing 
complex 2 and the rhodamine-azide 4 (25 μM treatment) shows identical localization 
(Fig 3.7d), which indicates similar cellular binding of both Pt 
complexes 1 and 2 independent of the click-functionalized moiety. Interestingly, however, 
Pt(II)-concentration-dependent post-treatment labeling in the HeLa cell line shows a 
dramatic difference in the observed fluorescent signal between these two complementary 
click compounds. Despite the similar localization of 1 and 2, there is significantly less 
fluorescent signal following 25 μM cellular treatment with 2, using identical conditions. 
HeLa cells were also treated individually with 5 μM complex 1 and 2 for 3 h followed by 
click labeling with the complementary rhodamine fluorophores. At this lower 
concentration, cells treated with the alkyne-appended complex 2 show no detectable 
fluorescent signal above background, but cells treated with azide-containing 1 present 
bright and distinct fluorescence (Fig 3.7j). Although we have not observed Pt-catalyzed 





well-reported that alkyne-containing compounds can undergo these reactions, which could 
lead to a decrease in fluorescent signal in-cell.40 The hydrophobicity of alkynes in 
comparison to their azide counterparts may also have an effect on accumulation or 
reactivity in the cell. These promising results show the potential of compound 1 not only 
for further localization studies in different cancer cell lines, but also for ongoing goals of 
isolating and identifying Pt(II)-bound targets using click chemistry. 
 
Figure 3.7. Confocal image of fluorescent cellular localization. Panel (b) shows the 
fluorescent labeling of HeLa cells treated with 1 (25 μm, 3 h) and subsequent click with 
rhodamine alkyne 3. The Cu-free control (f) shows no fluorescence. Panel (d) shows the 
fluorescent labeling of HeLa Cells treated with 2 (25 μm, 3 h) after fixation, 
permeabilization, and labeling with the rhodamine azide 4 in the HeLa cell line and Cu-
free control (h). Panel (j) shows an enlarged image of the fluorescent labeling of HeLa cells 
treated with 1 (5 μm, 3 h) and subsequent click with rhodamine alkyne3. The overlay of 








 In summary, we have developed a novel azide-containing Pt(II) complex (1) and 
compared it to its alkyne-containing congener (2), and we report here for the first time the 
post-treatment fluorescent labeling of a bifunctional cisplatin-based Pt(II) complex in the 
HeLa cancer cell line. The exchange of the alkyne to the azide moiety leads to a completely 
different arrangement in the solid state, with the alkyne-containing 2 forming a circular 
arrangement dominated by CH/π(C≡C) hydrogen bonds and secondary Pt–Pt dimer 
interactions. In contrast, the arrangement of the azide analogue is dominated by Pt–Pt dimer 
formation and hydrogen bonding forming a 1D-zigzag chain. In solution both complexes 
bind similarly to a DNA hairpin and show similar click reactivity in post-binding 
fluorescent labeling using complementary click-modified rhodamine fluorophores. Not 
only were we able to show the utilization of 1 as a cross-linking agent for larger 
biomolecules, but we also demonstrated its faster click reactivity in comparison to a 
previously described azide-containing Pt(II) complex. Finally, we report the first post-
treatment fluorescent labeling of a cisplatin-like bifunctional Pt(II) complex in HeLa cells, 
observing Pt(II) localization in the nuclei and distinctively in the nucleoli. Concentration-
dependent localization showed stronger fluorescent signals using the azide 1 versus the 
alkyne2 Pt complex. These results show the potential of the novel compound 1 for further 
cell-line-dependent localization studies and the isolation of Pt(II)-bound targets. 
 
Summary of Chapter III and Bridge to Chapter IV 
In this chapter we analyzed the binding of 1 and 2 to in vitro DNA. Complex 1 shows a 





reactivity to fluorophore conjugation in comparison with 2. When compared to its parent 
compound 5, 1 shows a similar increased ability to append a fluorophore by the azide-
alkyne click reaction. This difference in reactivity between 1 and 2/5 shows that the 
enhanced reactivity of 1 is most likely due to its longer linker to the azide substituent. 
Treatment of HeLa cells reveals that 1 and 2 show strong localization within the nuclei, 
most likely the nucleoli, with localization also present in the cytoplasm. These initial results 
within an imaging context are encouraging, but we were then motivated to improve the 
ability to detect Pt species at even lower concentrations. For this reason, in Chapter IV we 








DOUBLE POST-BINDING FLUORESCENT CONJUGATION AS A MEANS TO 
VISUALIZE CELLULAR DISTRIBUTION OF AN AZIDE-APPENDED PT(II) 
COMPLEX 
 
 This chapter contains contributions from Regina M. Wirth, Dr. Jonathan D. White, 
Alison Wallum, Prof. Michael M. Haley and Prof. Victoria J. DeRose. MMH and VJD 
provided insight and direction through the course of this investigation. RMW conducted 
the synthesis of the Pt complex and the Si-Rhodamine fluorophore under the advisement 
of JDW. All cell studies and analyses were conducted by myself. Under my advisement, 
AW performed all HPLC analysis and in vitro fluorescent characterization of the doubly 
conjugated fluorophore-Pt-DNA species. This chapter contains material reproduced from 
portions of a manuscript being prepared for submission to Nature Chemical Biology, co-
authored by myself, RMW, JDW, AW, MMH, and VJD. 
 
Introduction 
Since the discovery of their biological activity in the mid-1960s, Pt(II)-based 
chemotherapeutics have been used ubiquitously in anticancer treatment regimes. Their 
anti-proliferative effects are broadly ascribed to interactions with genomic DNA, causing 
inhibition of transcription and other processes.1-3 Used in ~50% of prescribed 
chemotherapies, effective use of this vanguard class of metal-based therapeutics is 
hampered by relatively severe side effects as well as both intrinsic and acquired 





with a wide variety of biological nucleophiles, including proteins, RNAs, and small 
molecules such as glutathione.  The extent and timing of these interactions, and their 
consequences on cytotoxicity, cellular resistance mechanisms, and alternative apoptotic 
signaling, are poorly understood.1-3,8,9 A comprehensive description of organelle-specific 
cellular Pt localization is currently incomplete, and new strategies to study the reactivity of 
Pt drugs and identify all cellular targets of Pt are needed.10  
To better track Pt compounds in vivo, we have developed Pt(II) reagents modifed 
with small, minimally invasive bioorthogonally reactive handles that allow post-treatment 
labeling by alkyne-azide cycloaddition ‘click’ reactions for visualization and 
identification.11 Here, we report a new method to improve resolution of Pt-bound species 
in cellulo that includes a double-click reaction to add multiple fluorophores per Pt reagent 
(Fig 4.1). This method is extended to a near-IR ‘turn-on’ silicon-rhodamine-azide 







Figure 4.1. Post-treatment covalent modification of 1 with rhodamine B (2 and 3) or ‘turn-
on’ silicon-rhodamine fluorophores (4). HeLa cells treated with 5 μM 1 are subsequently 
fixed, permeabilized, and then reacted with either alkyl-rhodamine B (2) or 
tripropargylamine under click conditions. In the double-click protocol, the latter are further 
reacted with either the Si-rhodamine-azide or rhodamine-B-azide under click conditions 
and imaged via confocal microscopy. See Appendix C for full experimental conditions. 
Applications of post-binding fluorescent labeling reactions using modified Pt 
complexes have been limited. Using a monofunctional azide-modified Pt-acridine 
complex, Bierbach and colleagues observed nuclear and intense nucleolar accumulation in 
cultured lung carcinoma cells after 3 h treatment.16 Previous work from our group has 
shown rRNA to act as a de facto Pt sponge,17 making it all the more interesting that intense 
Pt accumulation is seen at the site of ribosome biogenesis in the nucleoli. Using click-
enabled Pt(II) reagent 1 and its alkyne counterpart, we have recently imaged Pt-bound 
species in HeLa cells,15 also finding intense nucleolar localization along with intensity in 
the nucleus and cytoplasm. In an attempt to increase brightness of these images, we 
envisioned an intermediate click reaction to attach multiple fluorophores to a Pt target.  In 





performed a second click ligation with azide fluorophores to afford two fluorophores per 
Pt (Fig 1). Such “double” and “tandem” click reactions have been used in diverse 
contexts,18,19 however, to our knowledge, multi-click strategies have not been used for in-
cell imaging.  
Results 
To demonstrate our double-click method, we first compared the confocal 
fluorescence images of 1 with single- and double-rhodamine B labeling. After treating 
HeLa cells with the bifunctional Pt compound 1 followed by standard post-treatment click 
labeling with alkyne- fluorophore (2), we observe intense nucleolar fluorescence (Fig 
4.2A). Fluorescence intensity is dramatically increased, however, in cells treated with the 
‘double-click’ protocol (Fig 4.2B). Pt distribution in both sets of images appears to be quite 
similar, with intense localization in the nucleoli, along with tight localization around the 
nucleus and additional fluorescence in non-nuclear regions. In the brighter double-click 
images we are able to better resolve fine detail of Pt localization (Figure 4.2 C and D). The 
images acquired using the double click method show more detail even after post-
acquisition processing to equalize the brightness across all panels (Figure S1, see 
Appendix D). As demonstrated by intensity line plots, images captured using the double-
click method are not only brighter than those with single fluorophore attachment, but also 
show better resolution between nucleoli and nuclear regions (Figures 4.2E and F). This 
double-label method with rhodamine fluorophores does not result in fluorophore self-
quenching, as demonstrated by fluorescence yield measurements on in vitro DNA 







Figure 4.2. HeLa cells treated with 1 and then subjected to ‘single’- (A) or ‘double’- (B) 
click (Figure 1) with rhodamine fluorophores. (A) 5 µM treated HeLa cells post-labelled 
with the single-click protocol. (B) 5 µM treated HeLa cells post-labelled with the double-
click protocol. Scale bars 10 µm. Panels (E) and (F) show intensity line plots for the arrows 
drawn in 2x magnified images (C) and (D). Images were acquired using the same laser and 
similar acquisition settings (Appendix C) and shown unprocessed for comparison. Images 






To reduce background in the imaging of Pt-bound species we then pursued use of 
a turn-on near IR Si-Rhodamine fluorophore (4), first synthesized by Bertozzi and 
colleagues.15 The N3-Si-Rho fluorophore has low fluorescence intensity that exhibits a 50-
fold turn-on upon triazole formation, with absorbance and emission at 655/668 nm 
respectively.15 In the double-click reaction using 1-treated cells and standard N3-RhoB, in 
the absence of extensive washing, significant background fluorescence is observed in the 
–Cu control sample (Figure 3B,D). The azide-quenched Si-Rho fluorophore, however, 
shows no background fluorescence under the same conditions (Figure 3A). Following 
reaction with the Si-Rho fluorophore, brighter nucleolar intensity is observed than with 
RhoB (Figures 4.3C,D). In addition to bright nucleolar fluorescence, the comparison of 
Figures 4.3C,D with 2C,D also shows a brighter general nuclear fluorescence. Unlike the 
standard protocols for post-treatment labeling, the protocol used in Figures 4.3C,D 
minimizes the washing steps that are usually needed to remove unbound fluorophore (see 
Appendix D).  The nuclear fluorescence in Figure 4.3C, fully absent in the unclicked 
control sample (4.3A), is brighter than that observed with the standard double-click 
protocol (Fig 4.2) and suggests that use of the turn-on fluorophore allows imaging of some 







Figure 4.3. HeLa cells treated with 5 M 1 and then labelled with either rhodamine B 
azide fluorophore (B) or Si-Rhodamine fluorophore (A) using the double-click protocol 
with minimized washing steps. Panels A and B show the extent of the background 
fluorescence due to unbound fluorophore. Panels C and D reveal similar Pt localization, 
with the most abundant signal present in the nucleolus.  
Conclusions 
In summary, the double-click fluorescence labeling method presented here 
significantly improves visualization of azide probes within cells. Use of the double-click 
method in comparison to the traditional click conjugation shows similar localization of Pt-
bound biomolecules but with images that have improved detail and higher overall 
brightness. The ability to use azide-quenched fluorophores to locate azide-labeled probes 
significantly broadens opportunities for turn-on click labeling This method can easily be 
exported to other applications of azide detection as well as other means of visualization 





Summary of Chapter IV and Bridge to Chapter V 
 In this chapter we showed the ability of 1 to be post-modified with two fluorophores 
after treating HeLa cells for 3 h. Localization of the doubly-conjugated species showed a 
similar profile to what was previously seen with single fluorophore conjugation, except 
that double conjugation images showed greater brightness and contrast than singly 
conjugated species. In vitro experiments reveal that the doubly conjugated species does not 
exhibit strong fluorescent quenching, as its quantum yield is similar to that of the parent 
fluorophore. Use of a previously reported turn-on fluorophore 4 led to similar localization 
as was observed with 3, but with greatly reduced background. Ultimately, this work 
motivated us to explore if the localization present with these complexes depends on the 
identity of the cell type. In Chapter V, we explore the differences in localization of 1 in 








ANALYSIS OF PT LOCALIZATION IN MULTPLE CANCER CELL LINES USING 
FLUORESCENT MICROSCOPY AND AN AZIDE MODIFIED PT(II) COMPLEX 
 
 This chapter contains contributions from Regina M. Wirth, Emily Reister-Morris, 
Alison Wallum, Michael M. Haley and Prof. Victoria J. DeRose. MMH and VJD provided 
insight and direction through the course of this investigation. RMW was responsible for all 
Pt synthesis. ERM was responsible for maintenance of all cell lines. AW, under my 
advisement, performed in-cell labeling of Pt in C6 cells. All cell studies utilizing the HCC 
1143 and MDA MB 468 cell lines were done by myself. This chapter contains material 
reproduced from portions of a manuscript being prepared for submission to American 




 Platinum-based therapeutics are ubiquitous in cancer treatments1-3, and the need to 
understand and eliminate the deleterious effects of these drugs remains critical. Our lab has 
developed methods to modify platinum reagents with a reactive handle to track and extract 
Pt targets within cells4-7. Most recently, we have shown that post-treatment 
functionalization of Pt compounds with fluorophores reveals intense Pt localization within 
the nucleoli7 of HeLa human cerivical cancer cells. Building on these results, here we probe 







Figure 5.1. Workflow for cellular imaging studies. Cells are incubated in 5 µM 1 for 3 h 
and then fixed, permeabilized and conjugated with Alexafluor 488 alkyne fluorophore 
through click chemistry. Cells are then washed and imaged via confocal microscopy. 
 
 Cisplatin has shown particularly high promise in the treatment of triple negative 
breast cancer (TNBC), an aggressive subtype consisting of ~15% of all breast cancers. 
TNBC is characterized by fast tumor growth and metastasis, and frequent relapse after 
treatment. TNBC cells lack estrogen and progesterone receptors as well as lack 
overexpression of her2/neu,8 all of which are important therapeutic targets. Since TNBC 
cells lack the ability to be treated through hormone therapy8 other methods using small 
molecule crosslinking agents such as Pt reagents are an important treatment route. 
Information about the drug response to cisplatin in TNBC cells can provide insight into 
mechanisms by which the drug functions as well as lead to improvement in therapeutic 
approaches. Because of this, we decided to investigate the localization of our azide-
modified complex 1 within two different TNBC cells, HCC 1143 and MDA MB 468 cells8. 
These cell lines have been previously well-characterized with respect to drug response. In 
examining a number of different TNBC cell lines, we chose these two lines because of their 
reported responses to Pt treatment. While both sensitive to cisplatin, these cell lines differ 
in that HCC1143 cells are reported to have a slightly lower response to cisplatin than MDA 
MB 468 cells.  As a comparison, we also chose to investigate Pt localization with C6 glioma 





types9. Some gliomas in both the human and rat cell lines have shown an increased 
glutathione response upon cisplatin treatment10. Glutathione, a tripeptide bearing a thiol 
moiety, is known to contribute to Pt resistance in cancer cells11. C6 cells have been shown 
to have greater amounts per cell of both glutathione and other antioxidants, of which could 
contribute to their resistance to Pt12. Differences in localization of the drug within this cell 
type could help elucidate what affects drug resistance. 
Results 
 Imaging the Pt localization in the two TNBC cell lines after 3-hr treatment with 1 
revealed quite varied results. The MDA MB 468 cells had localization differences within 
its own population (Fig. 5.2). All cells within the MDA MB 468 cell line exhibited strong 
fluorescence in the nucleolus, but some cells showed similar intensity within the nucleus 










Figure 5.2. MDA MB 468 cells labeled with DAPI, Alexa Fluor 488 alkyne and Mito 
Tracker Deep Red. The top panel shows the DAPI, Alexa Fluor 488/Pt and the Mito 
Tracker Deep Red images in greyscale. Images from the Alexa Fluor and Mito Tracker 
Deep Red channels are shown as well as an overlay of those two channels (Alexa Fluor in 
green and Mito Tracker Deep Red in red). 
 
 In particular, the Pt signal appears somewhat brighter in a ring around the nucleus. 
We postulated that this region might be mitochondria. Indeed, mitochondria stained with 
Mito-Tracker Deep Red (Invitrogen) do appear as a ring around the nucleus in these MDA 
cells (Figure 2C) and there is overlap between the fluorophore-labeled Pt and the Mito-
Tracker signal (Figure 2D). To determine if localization was more pronounced in the 
mitochondria than in other regions of the cells (outside of the nuclei), we quantified average 
fluorescence intensity across the selected areas inside and outside the mitochondria (see 







Cell Type (Location) Average Fluorescence 
MDA MB 468 (inside 
Mito) 
660 ± 91 
HCC 1143 (inside Mito) 480 ± 100 
MDA MB 468 (outside 
Mito) 
568 ± 189 
HCC 1143 (outside Mito) 522 ± 194 
Table 5.1. Average fluorescence of Alexafluor 488 channel inside and outside of Mito-
Tracker stained mitochondria. 
 
 The data in Table 1 indicate that the average Pt-Alexafluor fluorescence is not 
statistically higher inside the regions stained by Mito-Tracker, indicating that substantial 
localization to other extra-nuclear cell structures is occurring.  
 As a comparator, this experiment was repeated using HCC 1143 cells (Fig. 5.3). 
Unlike the MDA MB 468 cells, the HCC 1143 cells appear to be more homogenous in 
morphology and in Pt localization. HCC 1143 cells exhibited intense nucleolar Pt 
localization, and then broad localization within the nucleous and cytoplasm. Mito-Tracker 
staining reveals a more dispersed mitochondrial morphology for HCC cells than the tighter 
nuclear ‘ring’ observed in MDA cells.  Interestingly, in the cytoplasm there are dark areas 
where Pt localization is not present. These areas do not seem to coincide with the 








Figure 5.3. HCC 1143 cells labeled with DAPI, Alexafluor 488 alkyne and Mito Tracker 
Deep Red. The top panel shows the DAPI, Alexafluor 488/Pt and the Mito Tracker Deep 
Red images in greyscale. Images from the Alexa Fluor and Mito Tracker Deep Red 
channels are shown as well as an overlay of those two channels (Alexa Fluor in green and 
Mito Tracker Deep Red in red). 
 
 For further comparison, we measured Pt localization in the C6 glioma cell line. 
Unlike the HeLa, HCC 1143 and MDA MB 468 cells, the C6 cells have less well-defined 
nucleoli. While Pt is observed to localize to the nucleus, a strong nucleolar localization is 
not observed (Fig 5.4). This could be due to differences in C6 cell morphology and 
response to Pt when compared to other cell lines10. Upon Pt treatment, C6 cells undergo 






Figure 5.4. C6 cells labeled with DAPI and Alexa Fluor 488 alkyne. The left panel 
shows a greyscale image of the DAPI stain, the middle panel Alexa Fluor 488 alkyne, 




 Cellular imaging of TNBC cells reveal intense localization of 1 within the nucleoli 
of both cell lines. MDA MB 468 cells exhibited variance in localization, with localization 
intensity differences between the cytoplasm and nucleus. HCC 1143 cells exhibited more 
homogenous localization across the population of cells. C6 did not appear to have the same 
intense nucleolar localization. This could be due in part to the varied morphological 
response that C6 cells have to Pt treatment. C6 cells pre-treated with cisplatin have shown 
elevated glutathione levels which could influence this cell type’s elevated resistance. 
Moreover, longer treatment times with cisplatin have been shown to result in nucleolar 
segregation within C6 cells. Glutathione depletion within glioma cells has been shown to 
increase cisplatin sensitization12. The lack of strong nucleolar localization could be due to 
either factor, or a combination of the two. Further studies need to be done to ascertain if 








Summary of Chapter V and Bridge to Chapter VI 
 In this chapter we explored the localization of 1 within three different cell types. In 
the TNBC cells, 1 exhibited a similar localization as it did within HeLa cells, ultimately 
showing a strong targeting of the nucleoli. MDA MB 468 cells showed varied 
morphological differences. While all cells within that line showed strong nucleolar 
localization, there were variations in localization in the cytoplasm and nuclei. HCC 1143 
cells showed much more homogenous localization, still favoring the nucleoli. C6 glioma 
cells did not show a strong nucleolar localization. This could be due to differences in 
morphology of the cell line with respect to HeLa/HCC 1143/MDA MB 468 cells, or it 
could be due a glutathione response. For this reason, we wanted to pursue the construction 
of another Pt-azide derivative based on a carboplatin scaffold. Carboplatin has shown 
slower kinetics in comparison to cisplatin and it may have a greater resistance to react and 








SYNTHESIS AND ANALYSIS OF TWO AZIDE-MODIFIED CARBOPLATIN 
MIMICS TO BE USED IN POST-TREATMENT FUNCTIONALIZATION 
 
 This chapter contains contributions from Matthew M. Cerda, Rachael M. 
Cunningham, Michael M. Haley and Prof. Victoria J. DeRose. MMH and VJD provided 
insight and direction through the course of this investigation. MC, under my advisement, 
was responsible for the synthesis of 1 and 3. The synthesis of 2 and 4 were carried out by 
myself. RCM was responsible for the binding of 2/4 in bovine serum albumin as well as 
the SDS-PAGE analysis. 
 
Introduction 
 Despite its clinical success, cisplatin has also suffered from a number of toxicity 
issues such as nephrotoxicity, ototoxicity, and overall dose-limiting toxicity.1 To reduce 
these effects, other drugs such as carboplatin were developed.1 The relative toxicity of 
cisplatin in part stems from its aquation kinetics, as the aquated complex is considered to 
be the active form of the drug. The design rationale for carboplatin is to create a drug that 
resists aquation by installing a chelating leaving group.2 This resistance will slow reaction 
kinetics with biomolecules, and lower the overall toxicity.2 Carboplatin also maintains the 
same exchange-inert ammonia ligands such that the active form of carboplatin should still 
be the same as cisplatin. Overall, this has created a complex that targets the same types of 
cancers as cisplatin, while still reducing the other types of toxicities previously discussed. 





of the head and neck and bladder cancers carboplatin has shown limited efficacy.2 The 
question remains, is this limited efficacy caused by the lowered toxicity or differential 
biomolecule targeting by these two Pt complexes. 
 
 
Figure 6.1. FDA-approved Pt-based anticancer drugs: cisplatin, carboplatin and 
oxaliplatin. 
 
 In an effort to understand localization of Pt(II) reagents in cells, our lab has 
developed a number of derivatives that have been modified with either an azide or alkyne 
reactive handle for post-treatment fluorescent labelling.3-6 Recently, we endeavored to 
synthesize a carboplatin derivative with similar structure to our cisplatin mimics and 
compare the localization and behavior of the two complexes. Work toward this end would 
help answer the question of whether the slower aquation kinetics induced by the 
cyclobutanedicarboxylate substituent has an effect on localization and targeting of the Pt 









Figure 6.2. Azide and alkyne modified Pt(II) complexes synthesized in our lab. 
 
Results 
 We had previously reported on the use of 3 for post-treatment analysis and its 
interesting isomerization bias as revealed by RP-HPLC2. Uranker and co-workers 
developed the synthesis of 3 as well as the synthesis of 1.11 Interestingly, in attempting to 
make 1 by the methods listed, we encountered issues of low yield and intractable Pt 
impurities; the treatment of cyclobutanedicarboxylic acid with base (sodium hydroxide or 
DBU) in the presence of 3 did not generate appreciable amounts of 1, and hydroxide 
coordination of Pt may have been taking place over coordination by the carboxylic acid. 
This led us to pursue a different synthetic route using a silver salt of the acetate. The silver 
salt eliminates the need for base, and accelerates the reaction by precipitating the chloride 
ligands. This route afforded us both complex 1 and the novel compound 2 in moderate 







Figure 6.3. Synthetic scheme for 1 and 2. 
 
 Complex 1 was further used to demonstrate post-treatment analysis in vitro using a 
hairpin DNA construct (Fig 6.3). Utilizing the scheme in Figure 6.4A we used 1 to bind 
and then functionalize the DNA-Pt species with a rhodamine B fluorophore (Fig 6.4C) 
using the copper-catalyzed click reaction. As shown in Figure 3B, dPAGE analysis shows 
a mass shift of the hairpin DNA upon binding of 1 and again another mass shift upon 
fluorophore conjugation. Further studies need to be pursued to ascertain the influence of 







Figure 6.4. General scheme for binding of 1 to HP-DNA (A) and dPAGE analysis (B). For 
the click reaction, a rhodamine B alkyne-modified fluorophore was used (C). 
 
 We also investigated the ability of 2 to bind to bovine serum albumin (BSA), 
followed by fluorophore conjugation. After 6 and 24 h of incubation of BSA with 2, we 
are able to see the presence of fluorophore-Pt-BSA species via SDS PAGE. Furthermore, 
when we compare it to 4 at the same time points we see a similar response. Interestingly, 
we do not see a pronounced decrease in reactivity of 2 as might be expected if slower 
aquation kinetics were governing the yield of the Pt-BSA conjugate. More studies need to 






Figure 6.5. SDS PAGE analysis of 2 and 4 bound to BSA and conjugated to a rhodamine 
B fluorophore after incubation for 6 and 24 h.  
 
Conclusions and Future Directions 
 We were able to successfully synthesize two azide-modified Pt complexes bearing 
cyclobutanedicarboxylate as leaving group through a newly explored synthetic route 
generating the Ag-carboxylic acid salt as a precursor. Preliminary studies have shown that 
1 is able bind DNA in a similar manner to its parent compound 3, and is able to undergo 
post-treatment fluorophore conjugation through Cu-catalyzed click chemistry. Treatment 
of BSA with 2 shows similar results as 4, indicating its efficacy to be used in post-treatment 
analysis. Further studies need to be done to ascertain the relative reactivity between 1 and 
3, as well as the general reactivity of 2 to biomolecules. It is also of interest to see if the 
same isomerization bias witnessed with 3 is present with 1. This bias could be influenced 
by the size and aquation ability of the respective Pt complexes. Lastly, it is important to 





present on them could give insight on the relative in cell kinetics of cisplatin and 









 Having developed a wide array of different click-enabled Pt(II) complexes, in this 
work we have explored how we can visualize their distribution in cells, improve certainty 
of their localization, and categorize their localization differences in different cell types. 
The use of the newly synthesized Carbazaplatin could help us gain insight to how other Pt 
drugs like Carboplatin interact with cells, and could help elucidate resistance pathways and 
mechanisms. Ultimately, using these constructs we can also better pinpoint Pt specific 
targets through post-treatment biotinylation followed by enrichment and identification by 
sequencing or proteomics, a task our group is currently investigating. Also, another 
important task is understanding the behavior of Pt as a function of time, in terms of target 
identification and binding preferences in a cell. This ultimately could be aided by the use 
of cell permeable strained alkyne fluorophores, although the literature is currently lacking 
in that regard. A “snapshot” approach at varied time points could still help us understand 
what events are taking place. Another point of study could be correlating relative Pt-








 General Comments. Materials were purchased from commercial vendors and used 
without further purification. Anhydrous N,N’-dimethylformamide (DMF) was purchased 
from EMD Millipore (DriSolv). 1,3-Propanediamine was purchased from TCI America, 
KI and KCl were purchased from EMD, and AgNO3 was purchased from Strem Chemicals, 
Inc. K2PtCl4 was purchased from Sigma Aldrich and deuterated solvents were purchased 
from Cambridge Isotope Laboratories. 1H, 13C, and 195Pt NMR spectra were recorded in 
d7-DMF using a Varian Mercury 300  MHz (
1H: 300.09 MHz) or Bruker Advance III HD 
600 MHz (1H: 600.02 MHz, 13C: 150.87 MHz, 195Pt: 128.99 MHz) NMR spectrometer with 
a Prodigy multinuclear broadband cryoprobe. Chemical shifts (δ) are expressed in ppm 
relative to the residual DMF (1H: 8.03 ppm, 13C: 29.76) or the external reference K2PtCl4 
(195Pt: –1604 ppm). Gels were visualized with methylene blue stain and UV exposure 
(AlphaImager HP System). All DNA substrates were purchased directly from Integrated 
DNA Technologies, Inc., dissolved in nanopure ddH2O to a final stock concentration of 1 
mM, and used directly without further purification. 
cis-[Pt(2-azido-1,3-propanediamine)Cl2] (4). The azide-containing 4 was prepared 
according to the method of Urankar et al. (reference 8b in Chapter II). 
cis-[Pt(1,3-propanediamine)Cl2] (5). The azide-free 5 was prepared following the method 
described by Dhara for cisplatin (reference 9a in manuscript). Briefly, to a clear-red 
solution of K2PtCl4 (0.54 g, 1.31 mmol) in H2O (15 mL) was added KI (1.31 g, 7.87 mmol) 
in H2O (5 mL) and the reaction was stirred in the dark for 20 min. 1,3-Propanediamine 





another 2 h in the dark. The resulting yellow precipitate was then filtered and washed 
thoroughly with H2O and dried in a desiccator. All of the yellow solid (0.61 g, 1.17 mmol) 
was suspended in H2O (8 mL) to which AgNO3 (0.38 g, 2.22 mmol) in H2O (2 mL) was 
added at once. The mixture was stirred in the dark overnight (16.5 h). The opaque-tan 
mixture was filtered through a 0.2 μm syringe filter to reveal a clear-yellow filtrate. One 
drop of 1 M HCl was added to the filtrate, followed by 1.01 g KCl. The mixture was 
allowed to sit for 2 h in the dark at rt, after which a yellow solid was filtered from a clear-
yellow filtrate. The yellow solid was rinsed with H2O and dried in a desiccator to furnish 
the desired product (0.28 g, 0.83 mmol, 63%). 1H NMR (300 MHz, d7-DMF): δ 4.99 (Pt–
NH2–, s, 4H, 
3JPt-H = ~60 Hz), 2.88-2.60 (Pt–NH2–CH2–, m, 4H, obscured by residual DMF 
solvent peak), 1.78 (CH2–CH2–, m, 1H);
 13C NMR (151 MHz, d7-DMF): δ 43.2 (–NH2–
CH2–), 28.3 (–CH2–CH2–); 
195Pt NMR (129 MHz, d7-DMF): δ –2256 (Pt). HRMS (ESI) 
m/z calculated for C3H11N2Cl2Pt, 339.9947 (M
++H); found, 339.9932. 
5-(Dimethylamino)-N-(2-propynyl)-1-naphthalenesulfonamide (dansyl alkyne 
fluorophore). The dansyl alkyne was synthesized according to previously published 
methods (F. Bolletta, D. Fabbri, M. Lombardo, L. Prodi, C. Trombini, N. Zaccheroni, 
Organometallics, 1996, 15, 2415-2417). 
Platinum Activation (aquation). Picazoplatin (1), cis-[Pt(2-azido-1,3-
propanediamine)Cl2] (4), or cis-[Pt(1,3-propanediamine)Cl2] (5) (5 µmol) was added to a 
solution of AgNO3 in ddH2O (10 mM, 1 mL). The solution was incubated at 50 °C for 4 to 
18 h with stirring, at which time AgI precipitated as a white solid and was separated by 





for DNA and RNA binding studies. Solutions were stored in the dark at 4 °C and used for 
up to one week. 
Platinum–DNA Binding (HPLC analysis). The DNA duplex (280 µM each of 5’-
T5GGT6-3’ and 5’-A6CCA5-3’, typically 28 nmol) or the DNA hairpin (280 µM of 5’-
TATGGTATTTTTATACCATA-3’, typically 28 nmol) was folded by rapid heating to 90 
°C and slow cooling to 4 °C in 10 mM Na2PO4 (pH  7.1), 0.1 M NaNO3, and 10 mM 
Mg(NO3)2. An activated solution of 4 or 5 was added in equimolar proportions (for HPLC) 
or two-fold excess (for click reactions) and the solution was incubated at 37 °C for approx. 
16 h. Pt-bound DNA was purified with Sephadex G-25 Medium size exclusion resin (GE 
Healthcare) on laboratory-prepared spin columns (BioRad) to remove unbound Pt. 
Platinum–DNA Binding (PAGE analysis). The DNA duplex (280 µM each of 5’-
T5GGT6-3’ and 5’-A6CCA5-3’, typically 28 nmol) was folded by rapid heating to 90 °C 
and slow cooling to 4°C in 10 mM Na2HPO4/NaH2PO4 buffer (pH  7.1), 0.1 M NaNO3, 
and 10 mM Mg(NO3)2. An activated solution of 1 or 4 was added in twofold excess and 
the solution was incubated at 37 °C for 16 h. Pt-bound DNA was purified with Sephadex 
G-25 Medium size exclusion resin (GE Healthcare) on laboratory-prepared spin columns 
(BioRad) to remove unbound platinum. 
Platinum–DNA Click Reactions. Sodium ascorbate (18 µL, 10 mM), CuI (18 µL, 10 
mM), dansyl alkyne (10 µL, 2mM), and Et3N (10 µL, 7.2 M) were added to a solution 
water:acetonitrile (98:2) of Pt-bound DNA (18 µL, 180 µM). The samples were incubated 
at 50 °C for 30 min to 4 h. The samples were then purified with Sephadex G-25 Medium 
spin columns. The samples were dried in vacuo and then re-suspended in an equal volume 





HPLC Conditions. DNA was separated using reverse-phase HPLC (Akta purifier; 
Amersham Biosciences) on a C18 column (Hypersil GOLD, 5 mm 4.6/250 mm; Thermo 
Scientific). A mobile phase of 10 mM triethylammonium acetate (TEAA) and 80% 
acetonitrile/20% 10 mM TEAA were used. A multistep gradient was used that provided 
baseline separation of major peaks. 
Molecular Modeling. DFT calculations were performed using a model from an NMR 
solution structure of cisplatin-bound DNA (pdb: 3LPV, reference 9 in manuscript) in 
Spartan ’10 (Wavefunction Inc.) Version 1.1.0. The ammine ligands of cisplatin were 
replaced with 2-Azidopropane-1,3-diamine, and the bond angles and bond distances 
resulting from 4 bound to the two guanine residues were restricted (see below). The DNA 
atoms were held static while the equilibrium geometry of Pt was calculated using molecular 
mechanics (MMFF). The structures were then imported into PyMOL for visualization. 
Bovine Serum Albumin Platination and Click Reaction Conditions. BSA (50 μM) was 
incubated with 0, 50, 100, or 250 μM 4 in 10 mM Na2HPO4/NaH2PO4 buffer (pH 7.0), 10 
mM NaNO3, and 100 μM Mg(NO3)2 at 37 °C for 16 h. Pt-bound BSA was purified with 
Sephadex G-25 Medium size exclusion resin (GE Healthcare) on laboratory-prepared spin 
columns (BioRad) to remove unbound Pt. To perform the click reaction, 100 μM dansyl-
alkyne fluorophore, 100 μM CuSO4, and 2 mM sodium ascorbate was added to platinated 
BSA and allowed to react at 37 °C for 1 h. Free fluorophore was removed using Sephadex 
G-25 spin-columns. Purified protein was then analyzed by 10% SDS-PAGE. 
S. cerevisiae Treatment with 4. Liquid cultures of S. cerevisiae strain BY4741 (MATa; 
his3Δ1; leu2Δ0; met15Δ0; ura3Δ0), a gift from the Tom Stevens laboratory at the 





medium (0.67% yeast nitrogen base and 2% glucose supplemented with amino acids and 
nucleotide bases). Overnight cultures were diluted to OD600 ~0.25 in synthetic dextrose 
medium supplemented with 0 or 250 µM 2-ADAP Pt. Cells were grown at 30 °C for 6 h 
with aeration, harvested by centrifugation at 4000 rpm at 4 °C, resuspended in fresh 
medium, and returned to shaker at 30 °C. At 0, 40, 80, and 120 min post treatment, aliquots 
were harvested by centrifugation at 4000 rpm, supernatant was discarded, and pellets were 
stored at –20 °C. Total RNA was extracted with the MasterPure Yeast RNA Purification 
Kit (Epicentre) according to a modified manufacturer’s protocol. RNA concentration was 
calculated using absorbance at 260 nm. For the click reaction, 8-14 µg of total RNA 
(normalized to OD600 of initial culture at timepoint collected) was incubated overnight at 
37 °C in a 10 µL reaction mixture containing 20 U RiboGuard RNAse Inhibitor and 0.25 
mM Alexa Fluor 488 DIBO. Unbound fluorophore was removed using an RNeasy Mini 
Kit (Qiagen) according to a modified manufacturer’s protocol. Samples were diluted 2-
fold in formamide and analyzed on an 8% (29:1) mono/bis polyacrylamide gel. 
Fluorescence signal intensities from Fig. 6, normalized to RNA (methylene blue stain) and 
culture OD, are shown below indicating significant retention of Pt-rRNA adducts after 2 h 







Figure A.1. Normalized Pt-rRNA signal over time. Fluorescence signal from click reaction 












Figure A.2. Results of DFT calculations of 4 bound to DNA. DFT-calculated (B3LYP 6-
31G* with pseudopotentials) minimized ground-state geometry of 4 bound to the guanines 




























































Figure A.4. HPLC and dPAGE analysis of 4-bound hairpin DNA-Pt adduct following click 
reaction with dansyl alkyne. HPLC peaks at 5, 6, 14, 15, and 41-45 mL were isolated, 
rotary evaporated and then re-suspended for dPAGE analysis. In the first lane of the gel 
above is the crude reaction mixture, in lanes 2-9 are the corresponding HPLC fractions. 
The HPLC chromatogram on the right reveals that when the absorbance values for the 
fluorophore are multiplied by a factor of 21 the absorbance of the fluorophore bound to the 
clicked product can be easily seen and correlated to the corresponding click peaks. This 
multiplication is based upon the ratio between the extinction coefficient of the dansyl 







Figure A.5. HPLC chromatograms of the single stranded construct (ssDNA) and the 
double stranded construct (dsDNA) bound by 4. Normalized areas of DNA parent peaks, 
first and second platinum binding peaks are listed. The ratio of the Pt-DNA peaks are listed 
along with the average for each construct and their respective standard deviations. 
 
 
Figure A.6. Results from ESI-MS experiment. Traces for the parent DNA strand (green) 
and the two isolated 4 bound to DNA (blue and red traces) are shown. Peaks in the spectrum 
are attributed to the 3+ DNA strand (2031) and the 3+ 4-DNA strand (2133). Inset shows 









Figure A.7. HPLC chromatogram for dsDNA bound by 4 and clicked to a dansyl alkyne 
fluorophore. Peaks near 35 and 40 mL elution volume correlate to unbound DNA 
A6CCA5 and T6GGT5 respectively. Peak near 42 mL elution volume correlates to 4 
bound DNA. Peaks near 49 mL elution volume correlate to the clicked products. The 







Materials and Methods 
Materials were purchased from commercial vendors and used without further purification 
unless noted otherwise. Column chromatography was performed on Silica Gel Premium Rf 
(Sorbent Technologies, 75–200 μm). 1H, 13C, and 195Pt NMR spectra were recorded in 
CDCl3, d6-DMSO, or d7-DMF using a Varian Inova 500 MHz  (
1H: 500.11 MHz, 13C: 
125.76 MHz, 195Pt: 107.49 MHz) or a Varian Mercury 300 MHz (1H: 300.09 MHz) NMR 
spectrometer. Chemical shifts (δ) are expressed in ppm relative to the residual CHCl3 (
1H: 
7.26 ppm, 13C: 77.23 ppm), d6-DMSO (
1H: 2.50 ppm, 13C: 39.52 ppm), d7-DMF (
1H: 8.03 
ppm, 13C: 163.15 ppm) or the external reference K2PtCl4 (
195Pt: –1604 ppm).  
dPAGE experiments were visualized with methylene blue stain and UV exposure 
(AlphaImager HP System). Fluorescent images were obtained using an Olympus 
FluoViewTM FV1000 confocal microscope.  
DNA substrates were purchased directly from Integrated DNA Technologies, Inc., 
dissolved in nanopure ddH2O to a final stock concentration of 1 mM and used without 














Figure B.1. Synthesis of complex 1. 
 
Di-tert-butyl (2-aminopropane-1,3-diyl)dicarbamate (7):  
The dicarbamate 7 was synthesized according to methods in Appendix A. 
 
Di-tert-butyl [2-(4-azidobutanamido)propane-1,3-diyl]dicarbamate (8): 
To a 0° C solution of 4-azidobutanoic acid (0.77 g, 5.96 mmol) and 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide hydrochloride (1.27 g, 6.64 mmol) in dry CH2Cl2 (28 
mL) was added dropwise a solution of di-tert-butyl (2-aminopropane-1,3-diyl)dicarbamate 
(7) (1.20 g, 4.15 mmol) in dry CH2Cl2 (40 mL). The reaction was allowed to warm to rt 
and was stirred for 4 d. The reaction was then quenched with H2O (20 mL) and allowed to 
stir for ca. 45 min. The organic phase was separated and washed with basic (NaHCO3) H2O 
(3 x 50 mL), then mildly acidic H2O (ca. 1 M HCl, 3 x 50 mL), then dried with MgSO4 and 
evaporated in vacuo to give a white solid. The solid was recrystallized from boiling EtOAc 
to reveal another white solid (0.74 g, 45%). 1H NMR (500 MHz, CDCl3): δ 7.05 (CONH, 






s, 1H), 5.35 (NH, s, 2H), 3.74 (CH, s, 1H), 3.50-3.04 (NHCH2, m, 4H), 3.34-3.31 
(CH2CH2CH2, m, 2H), 2.25 (CH2N3, t, J = 7.3 Hz, 2H), 1.90 (CH2CH2CH2, p, J = 6.9 Hz, 
2H), 1.44 (t-Boc, s, 18H). 13C NMR (500 MHz, CDCl3): δ 172.5, 157.7, 80.1, 53.0, 51.0, 
40.9, 33.6, 28.5, 24.9.  
 
4-Azido-N-(1,3-diaminopropan-2-yl)butanamide dihydrochloride (9): 
To a flask charged with di-tert-butyl [2-(4-azidobutanamido)propane-1,3- 
diyl]dicarbamate (8) (0.32 g, 0.82 mmol) chilled on ice was added 4M HCl in 1,4-dioxane 
(7 mL). The mixture was stirred until all the solid had dissolved, then a new, white 
precipitate formed (ca. 1 h). The solid was filtered, rinsed with 1,4-dioxane followed by 
Et2O, then dried in vacuo overnight to furnish a white solid (0.175 g, 83%). 
1H NMR (500 
MHz, d6-DMSO): δ 8.50-8.00 (NH3/CONH, m, 7H), 4.20 (CH, s, 1H), 3.36 (NHCOCH2, 
t, J = 5.0 Hz, 2H), 3.10-2.85 (NH3CH2, m, 4H), 2.26 (CH2N3, t, J = 7.4 Hz, 2H), 1.79 
(CH2CH2CH2, p, J = 7.1 Hz, 2H). 
13C NMR (500 MHz, d6-DMSO): δ 172.5, 50.4, 45.3, 
39.9-39.8 (obscured by solvent peak), 32.4, 24.0.  
 
cis-[Pt(2-(4-azidobutyl)amido-1,3-propanediamine)Cl2] (1):  
To a solution of 4-azido-N-(1,3-diaminopropan-2-yl)butanamide dihydrochloride (9) 
(0.045 g, 0.17 mmol) and 1,8-diazabicycloundec-7-ene (50 μL, 0.33 mmol) in dry DMF 
(1.26 mL) was added cis-[Pt(DMSO)2Cl2] (0.070 g, 0.17 mmol). The reaction was sealed 
with a septum and stirred in the dark for 2 d. The clear-yellow reaction mixture was added 
to chilled H2O (4 mL) and the precipitate was isolated by filtration. The solid was washed 






(500 MHz, d7-DMF) δ (ppm) = 8.05-7.97 (NH, m, 1H, partially obscured by residual 
solvent peak), 5.38-5.08 (CH2NH2, m, 4H), 4.20-4.10 ((CH2)2CHNH, m, 1H), 3.41 
(CH2N3, t, J = 7.5 Hz, 2H), 2.85-2.69 (CH2NH2, m, 4H), 2.31 (COCH2, t, J = 7.5 Hz, 2H), 
1.85 (CH2CH2CH2, p, J = 7.5 Hz, 2H). 
13C NMR (500 MHz, d7-DMF): δ 172.3, 51.9, 48.4, 
47.4, 33.6, 25.7. 195Pt NMR (500 MHz, d7-DMF): δ –2287.  
 
4-Pentynyl Rhodamine-B Ester (Rhodamine alkyne) (5): 
To a solution of rhodamine-B (2.01 g, 4.20 mmol) in dry CH2Cl2 (50 mL) was added 4-
pentyn-1-ol (0.47 g, 5.59 mmol), N,N'-dicyclohexylcarbodiimide (1.34 g, 6.50 mmol), and 
4-dimethylaminopyridine (0.06 g, 0.49 mmol) and the reaction was stirred in the dark for 
18 h at rt. The purple reaction mixture was washed with H2O (3 x 50 mL) and the organic 
layer was evaporated to dryness in vacuo. The purple oil was purified via flash column 
chromatography on silica gel (100:10:1 CHCl3/CH3OH/CH3COOH, Rf ≈ 0.4). The 
combined fractions were evaporated in vacuo and purified again via flash column 
chromatography on silica gel (100:100:1 CHCl3/CH3OH/CH3COOH, Rf ≈ 0.8). The 
combined fractions were dried with MgSO4, filtered, and evaporated in vacuo to reveal a 
purple oil (801 mg, 35%). 1H NMR (500 MHz, CDCl3): δ 8.30-8.23 (Ar, m, 1H), 7.85-7.66 
(Ar, m, 2H), 7.32-7.27 (Ar, m, 1H), 7.09-7.01 (Ar, d, J = 9.4 Hz, 2H), 6.92 (Ar, dd, J = 9.5 
Hz, 2.2 Hz, 2H), 6.86  (Ar, d, J = 2.3 Hz, 2H), 4.12 (COCH2, t, J = 6.2 Hz, 2H), 3.62 
(NCH2, q, J = 7.2 Hz, 8H), 2.05 (CH2CCH, td, J = 7.7, 2.6 Hz, 2H), 1.90 (CCH, t, J = 2.6 
Hz, 1 H), 1.69 (CH2CH2CH2, p, J = 6.6 Hz, 2H), 1.32 (NCH2CH3, t, J = 7.1 Hz, 12H). 
13C 
NMR (500 MHz, CDCl3): δ 165.2, 158.9, 157.9, 155.8, 133.7, 133.3, 131.5, 131.4, 130.6, 





3 Denaturing Polyacrylamide Gel Electrophoresis – Experiments 
DNA Folding (Figure 3.4-6):  
The DNA (typically 5 nmol, 5’- TATGGTATTTTTATACCATA-3’) was folded by rapid 
heating to 90 °C and slow cooling to 4 °C in a 10 mM Na2HPO4 (pH 7.0), 100 mM NaNO3, 
and 1 mM Mg(NO3)2 solution to give a final volume of 13 μL. 
 
Platinum-DNA Hairpin Binding (Figure 3.4):  
A 2.5 mM solution of 1 or 2 in DMF was individually added to the folded hairpin                      
(equimolar amount vs. DNA), the solution diluted with 3 μL of ddH2O and incubated at 37 
°C for     18 h. The solution of 1-bound DNA or 2-bound DNA was purified with Sephadex 
G-25 Med. size exclusion resin (GE Healthcare) on laboratory-prepared spin columns 
(BioRad) to remove unbound 1 or 2. The eluent was dried to completion by 
SpeedVac and stored at –30 °C until use.  
Platinum-DNA Hairpin Click Reaction (Figure 3.4): 
The 1- or 2-bound DNA pellet was re-suspended in H2O (18 μL) and Na2HPO4 (pH 7.0, 
3.7 μL, 100 mM), to which was added rhodamine alkyne/azide (2 μL, 5 mM), sodium 
ascorbate (5 μL, 10 mM), and finally CuSO4 (5 μL, 1 mM). The reaction was left for 18 h 
at rt. Upon completion of the reaction the mixture was purified with Sephadex G- 25 Med. 
resin on laboratory-prepared spin columns to remove Cu and to quench the reaction. The 
eluent was dried to completion by SpeedVac and re-dissolved in H2O (18 μL) and 70% v/v 
formamide (12 μL) for analysis by dPAGE (20%, 29:1).  
 





A 5 mM solution of 1 or 2 in DMF was individually added to the folded hairpin                      
(twofold access vs. DNA), the solution diluted with 3 μL of ddH2O and incubated at 37 °C 
for 48 h. The solution of 1- or 2-bound DNA was purified with Sephadex G-25 Med. size 
exclusion resin (GE Healthcare) on laboratory- prepared spin columns (BioRad) to remove 
unbound Pt. The eluent was dried to completion by SpeedVac and stored at –30 °C until 
use.  
 
Platinum-DNA Hairpin Click Reaction (Figure 3.5): 
The 1- and 2-bound DNA pellets were re-suspended in ddH2O (18 μL), Na2HPO4 (pH 7.0, 
3.7 μL, 100 mM) and both solutions were combined. Sodium ascorbate (10 μL, 10 mM), 
and CuSO4 (10 μL, 1 mM) were added and the reaction left for 24 hours at rt. The mixture 
was purified with Sephadex G-25 Med. resin on laboratory-prepared spin columns to 
remove Cu and to quench the reaction. The eluent was dried to completion by SpeedVac 
and re-dissolved in H2O (18 μL) and 70% v/v formamide (12 μL) for analysis by dPAGE 
(20%, 29:1).  
Platinum-DNA Hairpin Click Reaction with Dansylalkyne/azide as internal control 
(Figure B.2): 
The 1- or 2-bound DNA pellet was re-suspended in H2O (18 μL) and Na2HPO4 (pH 7.0, 
3.7 μL, 100 mM), to which was added dansyl alkyne/azide (5-(dimethylamino)-N-(2-
propynyl)-1-napthalenesulfonamide, 5-(Dimethylamino)naphthalene-1-sulfonyl azide) (2 
μL, 10 mM), sodium ascorbate (5 μL, 10 mM), and finally CuSO4 (5 μL, 1 mM). The 
reaction was left for 24 h at rt. Upon completion of the reaction the mixture was purified 





to quench the reaction. The eluent was dried to completion by SpeedVac and re-dissolved 
in H2O (18 μL) and 70% v/v formamide (12 μL) for analysis by dPAGE (20%, 29:1).  
 
Figure B.2.  dPAGE experiment showing the crosslinking of 1 and 2 bound to a 5’-GG-3’ 
DNA hairpin sequence (f). The internal controls are depicted in lane d and e (Platination 
of the DNA with 1 or 2 followed by subsequent CuAAC with dansyl alkyne/azide 
fluorophore). The copper free control is depicted in lane g. 
 





A 2.5 mM solution of 1 or 5 in DMF was individually added to the folded hairpin                      
(equimolar amount vs. DNA), the solution diluted with 3 μL of ddH2O and incubated at 37 
°C for   48 h. The solution of 1- or 5-bound DNA was purified with Sephadex G-25 Med. 
size exclusion resin (GE Healthcare) on laboratory- prepared spin columns (BioRad) to 
remove unbound Pt. The eluent was dried to completion by SpeedVac and stored at –30 °C 
until use.  
 
Platinum-DNA Hairpin Click Reaction (Figure 3.6): 
The 1- or 5-bound DNA pellet was re-suspended in H2O (18 μL), Na2HPO4 (pH 7.0, 3.7 
μL, 100 mM), to which was added dansyl alkyne (5 μL, 10 mM in DMF), sodium ascorbate 
(5 μL, 10 mM), and finally CuSO4 (5 μL, 1 mM). The reaction was left for 30 min. to 6 
hours at rt. Upon completion of the reaction the mixture was purified with Sephadex G- 25 
Med. resin on laboratory-prepared spin columns to remove Cu and to quench the reaction. 
The eluent was dried to completion by SpeedVac and re-dissolved in H2O (18 μL) and 70% 







4 Crystallographic Data 
 
X-ray Crystallography. Diffraction intensities were collected at 173 K on a Bruker Apex2 
CCD diffractometer using MoK radiation, = 0.71073 Å. Space group was determined 
based on intensity statistics. Absorption correction was applied by SADABS.(9) Structure 
was solved by direct methods and Fourier techniques and refined on F2 using full matrix 
least-squares procedures. All non-H atoms were refined with anisotropic thermal 
parameters. H atoms were refined in calculated positions in a rigid group model. All 
calculations were performed by the Bruker SHELXTL (v. 6.10)(10) and SHELXL-2013 
packages.(11) 
 
Crystallographic Data for 1: C7H16Cl2N6OPt, M = 466.25, 0.07 x 0.04 x 0.03 mm, T = 173 
K, triclinic, space group  P-1, a = 7.330(2) Å, b = 7.583(2) Å, c = 11.831(3) Å,  = 
85.465(5),  = 86.040(5),  = 86.498(5), V = 653.1(3) Å3, Z = 2, Dc = 2.371 Mg/m3, 
μ(Mo)= 11.147 mm–1, F(000) = 440, 2θmax = 50.0°, 7931 reflections, 2287 independent 
reflections [Rint = 0.0774], R1 = 0.0403, wR2 = 0.0644 and GOF = 1.011 for 2287 
reflections (154 parameters) with I>2(I), R1 = 0.0627, wR2 = 0.0704 and GOF = 1.011 








Figure B.3. Crystal structure arrangement of 1 showing the antiparallel arrangement of the 
azide moiety and hydrogen bonding between the amine protons and adjacent carbonyl 
group (2.13 Å) 
 
5 Confocal fluorescence microscopy 
Cell Maintenance: 
 The human cervical cancer cell line, HeLa, was obtained from the American Type Culture 
Collection (Rockville, MD, USA) and was cultured in DMEM media (gibco) containing 
4.5 g L D-glucose and 110 mg L sodium pyruvate supplemented with 10% fetal bovine 
serum (FBS) and 10% antibiotics. Cells were incubated at a constant temperature at 37 °C 
in a humidified atmosphere containing 5% CO2 and were subcultured every 2 to 3 days in 
order to maintain cells in logarithmic growth. 
Cell Treatment and Cu-Catalyzed Click:  
HeLa cells were seeded onto microscope cover slips with 1.5 x 105 cells/mL in 2 mL of 
media per well. Cells were incubated overnight and then treated with 5 μM or 25 μM 1 and 
2 for 3 h. Cells were then rinsed with PBS, fixed with 4% paraformaldehyde (in PBS pH 
7.4) for 20 min, and then permeabilized with Triton-X 100 (Figure 7) for 20 min. After 





then incubated with 1 mM CuSO4, 5 mM THPTA, 5 μM Rhodamine, 25 mM sodium 
ascorbate, and 100 mM phosphate buffer for 2 h at room temperature. Cells were then 
rinsed with 3% BSA in PBS (5 min), and then washed extensively with Triton X (2 x 10 
min) and then PBS 2x10 min. Slides were then mounted using ProLong Diamond anti-fade 
reagent with DAPI stain. 
 
6 NMR Spectra 
 
 







Figure B.5. 13C NMR spectrum of 8 in CDCl3 (500 MHz).  
 




















Figure B.9. 13C NMR spectrum of 1 in d7-DMF (500 MHz).   
 




















Materials and Methods 
For general HPLC methods refer to Appendix A. For general synthetic methods of 1 refer 
to Appendix B. 
Platinum–DNA Click Reactions (HPLC analysis). Sodium ascorbate (18 µL, 100 mM), 
a solution of CuSO4 (20 µL, 5mM) and tris(3-hydroxypropyltriazolylmethyl)amine 
(THPTA) (20 µL, 25 mM), tripropargylamine (10 µL, 2 mM) and 3 (10 µL, 2 mM) were 
added to a solution of water containing Pt-bound DNA (18 µL, 180 µM). The samples were 
incubated overnight at room temperature and then were fractionated via HPLC (see below). 
HPLC fractions were combined and dried in vacuo. Fractions corresponding to clicked 
product were again subjected to click reaction with 3 (10 µL, 2mM) in sodium ascorbate 
(18 µL, 25 mM), (20 µL, 5mM) and THPTA (20 µL, 25 mM). The samples were dried in 
vacuo and then resuspended in a 3:2 v/v mixture of ddH2O and formamide, respectively, 
for dPAGE analysis. Alternatively, the dried samples were dissolved in ddH2O for HPLC 
analysis. dPAGE experiments were visualized with methylene blue stain and UV exposure 
(AlphaImager HP System).  
Cell Maintenance 
The human cervical cancer cell line, HeLa, was obtained from the American Type Culture 
Collection (Rockville, MD, USA) and was cultured in DMEM media (gibco) containing 
4.5 g/L D-glucose and 110 mg/L sodium pyruvate supplemented with 10% fetal bovine 
serum (FBS) and 10% antibiotics. Cells were incubated at a constant temperature at 37 °C 
in a humidified atmosphere containing 5% CO2 and were subcultured every 2 to 3 days in 





Cell Treatment and Cu-Catalyzed Click  
HeLa cells were seeded onto microscope cover slips with 1.5 x 105 cells/mL in 2 mL of 
media per well. Cells were incubated overnight and then treated with 5 μM 1 for 3 h. Cells 
were then rinsed with PBS, fixed with 4% paraformaldehyde (in PBS, pH 7.4) for 20 min, 
and then permeabilized with Triton-X 100 for 20 min. After permeabilization, cells were 
washed with 3% BSA (in PBS, pH 7.4) twice for 10 min, and then incubated with 1 mM 
CuSO4, 5 mM THPTA, 5 μM tripropargylamine or 2, 25 mM sodium ascorbate, and 100 
mM phosphate buffer for 30 min at room temperature. Cells were then rinsed with 3% BSA 
in PBS (5 min), and then washed extensively with Triton X (2 x 10 min) and then PBS (2 
x 10 min). For the double-click procedure, cells were incubated again with 1 mM CuSO4, 
5 mM THPTA, 5µM 3 or 4, 25 mM sodium ascorbate, and 100 mM phosphate buffer for 
30 min at room temperature and then washed again extensively using BSA and Triton-X 
as noted above. Cells in Figure 3 were not washed after the second click reaction. Slides 
were then mounted using ProLong Diamond anti-fade reagent with DAPI stain. 
Fluorescent images were obtained using an Olympus FluoViewTM FV1000 confocal 
microscope using a 63x (PLAN APO 1.2 NA) objective lens. A 405 nm laser with an 
emission range of 430-470 was used to image DAPI staining in cells. For fluorophores 2 
and 3 a 543 nm laser with an emission range of 560-660 nm was used. For fluorophore 4 a 
635 nm laser with an emission range of 655-755 nm was used. All images were acquired 
at an 8 µs/pixel scan rate and 4x line averaging at 800 x 800-pixels. Images were acquired 
at an 8-bit sampling. All images were processed using ImageJ (National Institutes of 





to the same excitation power, PMT voltages, offset values and pinhole settings for each 
respective channel. 
3 Supplementary Figures 
 
Figure C.1. Line plots of the double and single clicked species with brightness levels 
enhanced post-acquisition. The lower panel shows a line plot of the double-clicked cells as 
shown in Figure 1. The top panel shows the single-clicked species line plot with brightness 







Figure C.2. Line plots comparing intensities in several double-clicked (panel A) and 
single-clicked (panel B) cells. Panel C shows background fluorescence for control cells 
treated with fluorophore but no Cu catalyst. In panel C the DAPI channel is shown in place 







Figure C.3. Fluorescence quantum yield measurements for 1-treated DNA hairpin with 
single- or double-fluorophore attachment. Panel A shows the HPLC chromatogram 
separating products from the single-click reaction (green) and product of the subsequent 
double-click reaction (blue). Products of 1-bound DNA include two isomers, as previously 
observed.(9)  Panel B shows the relative fluorescence intensities of the rhodamine azide, the 
DNA-Pt hairpin with a single rhodamine fluorophore, and the DNA-Pt hairpin with two 
attached rhodamine fluorophores. Fluorescence is normalized to the fluorophore 
concentration. Panel C shows the fluorescence quantum yield (PLQY) of each species, with 








Materials and Methods 
For general synthetic methods of 1 refer to Appendix B. 
Cell Maintenance 
All cell lines, HCC 1143, MDA MB 468, and C6 cells were obtained from the American 
Type Culture Collection (Rockville, MD, USA) and were cultured in recommended media 
(Gibco) at 37 °C in a humidified atmosphere containing 5% (HCC 1143 and C6) or 1% 
(MDA MB 468) CO2 and were subcultured every 2 to 3 days in order to maintain cells in 
logarithmic growth. 
Cellular Imaging 
Cells were seeded onto microscope cover slips with 1.5 x 105 cells/mL in 2 mL of media 
per well. Cells were incubated overnight and then treated with 5 μM 1 for 3 h. Cells were 
then rinsed with PBS, fixed with 4% paraformaldehyde (in PBS, pH 7.4) for 20 min, and 
then permeabilized with Triton-X 100 for 20 min. After permeabilization, cells were 
washed with 3% BSA (in PBS, pH 7.4) twice for 10 min, and then incubated with 1 mM 
CuSO4, 5 mM THPTA, 5 μM Alexafluor 488 alkyne (Invitrogen), 25 mM sodium 
ascorbate, and 100 mM phosphate buffer for 30 min at room temperature. Cells were then 
rinsed with 3% BSA in PBS (5 min), and then washed extensively with Triton X (2 x 10 
min) and then PBS (2 x 10 min). For co-localization experiments, before fixation the media 
was removed and cells were treated with 100 nM Mito-Tracker Deep Red (Invitrogen) for 
30 min in FBS free media. Slides were mounted using ProLong Diamond anti-fade reagent 





Fluorescent images were obtained using an Olympus FluoViewTM FV1000 confocal 
microscope using a 63x (PLAN APO 1.2 NA) objective lens. A 405 nm laser with an 
emission range of 430-470 was used to image DAPI staining in cells. For Alexafluor 488 
alkyne a 488 nm laser with an emission range of 500-570 nm was used. For Mito-Red 
tracker a 635 nm laser with an emission range of 655-755 nm was used. All images were 
acquired at an 8 µs/pixel scan rate and 4x line averaging at 800 x 800-pixels. Images were 
acquired at an 8-bit sampling. All images were processed using ImageJ (National Institutes 
of Health) and figures were prepared using Adobe Photoshop CC 2015. All images were 
held to the same excitation power, PMT voltages, offset values and pinhole settings for 
each respective channel. 
Co-localization Analysis 
For co-localization analysis, cell images were loaded into ImageJ (National Institutes of 
Health) and images were masked using the fluorescence present in the channel for Mito 
Tracker Deep Red. The average fluorescence intensity for the masked Alexafluor 488 
channel was calculated and then an inverse selection was made. Bounds for cells were set 
by the fluorescent image in Alexafluor 488 channel and the nucleus was masked using the 







For general synthetic methods of 3 refer to Appendix A. For general synthetic methods of 
4 refer to Appendix B. 
Synthesis of 1. To a stirred solution of 3 (48.6 mg) in H2O (5 mL), 5 (46.4 mg) was added 
and shielded from light for 48 h. The solution was then filtered through celite, and the celite 
column was rinsed 3 times with H2O (5 mL). The filtrate was placed under rotary vacuum 
to afford 1, a brown solid (31.3 mg, 53% yield).  1H NMR (500 MHz, d7-DMF): δ 4.99 (Pt–
NH2–, s, 4H, 
3JPt-H = ~60 Hz), 2.88-2.60 (Pt–NH2–CH2–, m, 4H, obscured by residual DMF 
solvent peak), 1.78 (CH2–CH2–, m, 1H);
 195Pt NMR (129 MHz, d7-DMF): δ –1950 (Pt).  
Synthesis of 2. To a stirred solution of 4 (15 mg) in a 50:50 mixture of H2O:DMF (10 mL), 
5 (17 mg) was added and shielded from light for 48 h. The solution was then filtered 
through celite, and the celite column was rinsed 3 times with H2O (5 mL). The filtrate was 
placed under rotary vacuum to afford 1, a yellow solid (5.1 mg, 31 % yield). 1H NMR (500 
MHz, D2O) δ (ppm) = 3.96-3.90 (m, 1H), 3.34-3.27 (t, 2H), 2.85-2.75 (q, 4H), 2.71-2.56 
(m, 4H), 2.33-2.22 (t, 2H), 1.85 (t, 4H). 195Pt NMR (500 MHz, d7-DMF): δ –1975. 
DNA Folding (Figure 3). The DNA hairpin (typically 5 nmol, 5’- 
TATGGTATTTTTATACCATA-3’) was folded by rapid heating to 90 °C and slow 
cooling to 4 °C in a 10 mM Na2HPO4 (pH 7.0), 100 mM NaNO3, and  100 mM Mg(NO3)2 
solution to give a final volume of 13 μL. 
Pt-DNA Hairpin Binding (Figure 3). 2µl of a 5 mM solution of 1 in DMF was added to the 





The solution of 1-bound DNA was purified with Sephadex G-25 Med. size exclusion resin 
(GE Healthcare) on laboratory- prepared spin columns (BioRad) to remove unbound Pt.  
Platinum-DNA Hairpin Click Reaction (Fig 6.3). The 1-bound DNA pellet was re-
suspended in H2O (18 μL), Na2HPO4 (pH 7.0, 3.7 μL, 100 mM), to which was added 
rhodamine alkyne (5 μL, 5 mM in H2O), sodium ascorbate (5 μL, 10 mM), and finally 
CuSO4 (5 μL, 1 mM). The reaction was incubated for 30 min at RT. Upon completion of 
the reaction, the mixture was purified with Sephadex G- 25 Med. resin on laboratory-
prepared spin columns to remove Cu and to quench the reaction. The eluent was dried to 
completion by SpeedVac and re-dissolved in H2O (18 μL) and 70% v/v formamide (12 μL) 
for analysis by dPAGE (20%, 29:1). 
Platinum-Bovine Serum Albumin (BSA) Binding with 2 (Fig 6.4).BSA (50 µM) was incubated 
with 250 µM 2 or 4 in 10 mM Na2HPO4/NaH2PO4 buffer (pH 7.0), 10 mM NaNO3, and 100 
µM Mg(NO3)2 at 37 °C for 6 or 24h. Pt-bound BSA was purified with Sephadex G-25 Medium 
size exclusion resin (GE Healthcare) on laboratory-prepared spin columns (Thermo Fisher) to 
remove unbound Pt. To perform the click reaction, 100 µM rhodamine B-alkyne fluorophore, 
125 µM CuSO4, 500 µM THPTA, and 2.5 mM sodium ascorbate was added to platinated BSA 
and allowed to react at 37 °C for 1 h. Free fluorophore was removed using Sephadex G-25 
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